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Extracorporeal membrane oxygenation (ECMO) 
is a form of extracorporeal life support utilized 
to rescue neonatal, pediatric, and adult patients 
with respiratory, cardiac, or combined cardiopul-
monary failure that is refractory to conventional 
supportive and therapeutic measures. As a modi-
fied form of cardiopulmonary bypass, modern-
day ECMO circuitry utilizes either a 
semi-occlusive roller pump or a centrifugal 
pump combined with a hollow fiber membrane 
oxygenator for gas exchange. As a supportive 
modality, ECMO can provide extended physio-
logic respiratory and cardiac support for days to 
weeks, thereby allowing the clinical team time to 
diagnose and treat the patient’s underlying dis-
ease process. To date, the Extracorporeal Life 
Support Organization registry contains more 
than 87,000 ECMO runs in its history, of which 
approximately 10% are children supported for a 
pulmonary indication [1].
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A 2-year-old girl has developed hypoxemic 
respiratory failure, severe pediatric acute 
respiratory distress syndrome, and sepsis 
secondary to influenza and Staphylococcus 
aureus pneumonia. On day 4 of mechanical 
ventilation, she is supported with high- 
frequency oscillatory ventilation with mean 
airway pressure set at 30  cmH2O.  Her 
inspired oxygen requirement is 70%, and 
she has been unable to be weaned over the 
past 12  h. Her arterial blood gas shows 
pH 7.26, PaCO2 65 mmHg, PaO2 58 mmHg, 
and base deficit  −  2. Epinephrine 
(0.06 mcg/kg/min) and dopamine (5 mcg/
kg/min) infusions are required for hemody-
namic support. Relevant clinical questions 
for the care of this child include:
• What clinical criteria can be utilized to 
determine if extracorporeal membrane 
oxygenation is indicated to support this 
child’s hypoxemic respiratory failure?
• Which extracorporeal modality and 
cannulation approach is most appropri-
ate in this clinical scenario?
• Which mechanical ventilation strategies 
and other respiratory therapies can help 
to optimize her chances of recovery?
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Despite the growing use of ECMO across 
critical care settings, a discrepancy exists in the 
available data regarding the effectiveness and 
benefit of ECMO for various patient popula-
tions. For neonates with refractory respiratory 
failure, clinical trials have shown that ECMO 
decreases mortality and is cost-effective [2–4]. 
Likewise, ECMO has been demonstrated to be a 
valid treatment option for critically ill adults 
with refractory respiratory failure, [5] yet no 
clinical trials evaluating the efficacy of ECMO 
have been performed for children with respira-
tory failure. Current evidence for use of ECMO 
for children with respiratory failure relies 
mostly on registry reports and single-center 
experiences. A recent secondary analysis of the 
RESTORE trial [6] utilizing matching tech-
niques to compare patients who did and did not 
receive ECMO showed no mortality benefit 
from ECMO as compared to ventilation man-
agement strategies [7]. This report, while 
thought provoking, was a secondary analysis of 
a study designed to evaluate a nurse- driven 
sedation protocol, and thus the results should be 
interpreted with caution. Examining ECMO in 
children with respiratory failure is further lim-
ited by the heterogeneity of this patient popula-
tion; variations in patient age, disease processes, 
and patient comorbidities all contribute to this 
heterogeneity. Lastly, the clinical management 
of ECMO varies greatly across pediatric 
centers.
Without reliable data by which to guide clini-
cal decision-making, pediatric intensivists man-
aging respiratory failure often must resort to their 
“gut feeling” when initiating and managing 
ECMO.  The stakes are high  – acuity of illness 
and rapid deterioration often do not allow much 
time for these life-saving decisions. 
Prognostication of outcome is difficult, and the 
costs (e.g., patient morbidity, financial burden, 
resource utilization) are potentially immense. 
Given these constraints, we attempt to summa-
rize the available literature regarding ECMO sup-
port for pediatric respiratory failure and provide 
an organized framework by which clinicians can 
make logical decisions for these challenging 
patients.
 Indications for ECMO
Indications for initiating ECMO in the setting of 
pediatric respiratory failure can be divided into 
two general frameworks (Table  2.1). The first 
clinical scenario is one of progressive hypoxemia 
and associated hemodynamic instability that 
remains refractory despite escalation in ventila-
tory support and other ancillary therapies. Quite 
simply, the child will die without ECMO, and the 
decision to initiate ECMO is not a difficult one. 
The second scenario is one in which the toxicities 
of medical therapy may begin to outweigh their 
clinical benefit. In the setting of respiratory fail-
ure and severe lung disease, the concept of 
ventilator- induced lung injury (VILI) becomes 
pertinent. Mechanical ventilation (MV) has been 
shown to initiate or worsen lung injury through 
the mechanisms of volutrauma, barotrauma, oxy-
gen toxicity, and atelectrauma [8]. Current rec-
ommendations to limit VILI in children with 
acute respiratory failure (ARF) include a low 
tidal volume strategy (5–8 mL/kg predicted body 
weight), limiting plateau pressures to <28 cmH2O, 
and titration of positive end-expiratory pressure 
(PEEP) in an effort to achieve alveolar recruit-
ment and reduce fraction of inspired oxygen con-
centration (FiO2) to non-toxic levels [9]. 
Permissive hypercapnia (maintaining a 
pH  >  7.25) and mild hypoxemia (PaO2 
Table 2.1 Indications for initiation of ECMO for respira-
tory failure
Rapidly progressive or severe hypoxemia resulting in 
hemodynamic instability and risk of cardiovascular 
collapse despite maximizing medical therapy
An oxygenation index sustained above 25 and not 
improving, combined with one sign of impaired tissue 
oxygenation:
  1. Rising serum lactate
  2. Widening arterial-venous saturation gradient
  3. Diminishing urine output
  4. Decreasing near-infrared spectroscopy (NIRS)
  5. Increasing need for vasoactive support
  6. Worsening metabolic acidosis
Hypercarbia and respiratory acidosis causing 
cardiovascular compromise
Presence of refractory or severe air leak syndromes 
compromising gas exchange or hemodynamic stability
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40–50  mmHg) are acceptable consequences of 
these maneuvers, provided adequate systemic 
oxygen delivery and hemodynamics are main-
tained [9]. In children with severe lung disease, 
these lung-protective strategies may have to be 
exceeded to provide adequate ventilation and 
oxygenation, with progressive VILI as an untow-
ard consequence. Initiating ECMO provides 
respiratory support allowing for reduction in ven-
tilator settings to non-toxic levels and possibly to 
avoid further VILI.  In either scenario, the most 
important principle when deciding upon ECMO 
suitability is to identify those children with a high 
probability of mortality yet having potentially 
reversible lung disease.
 Hypoxemic Respiratory Failure 
and Pediatric Acute Respiratory 
Distress Syndrome
Pediatric acute respiratory distress syndrome 
(pARDS) is a clinical syndrome characterized by 
decreased lung compliance and difficulties with 
oxygenation. Mortality from pARDS ranges 
from 18% to 35% [10, 11]. Clinical predictors of 
mortality from pARDS could help clinicians 
identify children who would benefit from ECMO 
support for refractory hypoxemic respiratory fail-
ure. Candidate predictors include alveolar dead 
space fraction (utilized in the studies below as 
[PaCO2 – end tidal CO2]/PaCO2), the PaO2/FiO2, 
and the oxygenation index (OI). Nuckton et  al. 
prospectively measured dead space fraction in 
adult patients with ARDS early in the course of 
their illness and found increasing dead space 
fraction to be an independent risk factor for mor-
tality [12]. From a pediatric perspective, in a ret-
rospective review of 217 children requiring 
mechanical ventilation for acute hypoxemic 
respiratory failure, the dead space fraction at dis-
ease onset and day one both correlated with mor-
tality, though not independently associated when 
controlled for severity of illness, 24-h maximal 
inotrope score, and oxygenation index [13]. On 
the other hand, in a cohort of 266 children with 
pARDS, Yehya et  al. recently showed that the 
alveolar dead space fraction at the onset of 
pARDS was significantly higher in non-survivors 
(0.31 vs 0.13), was independently associated 
with mortality, and functioned better as a predic-
tor of mortality than the initial PaO2/FiO2 ratio or 
oxygenation index [14]. This predictive value of 
dead space fraction however was not observed at 
24  h. Functionally, a single numerical value at 
disease onset may not be practical from the stand-
point of clinical decision-making, as intensivists 
may attempt other modalities and therapies (e.g., 
high-frequency oscillatory ventilation, prone 
position, inhaled nitric oxide, etc.) before pro-
ceeding with ECMO.
The PaO2/FiO2 (PF) ratio and the oxygenation 
index (OI = [(mean airway pressure × FiO2 × 100)/
PaO2]) have both served as markers of lung dis-
ease severity in children with hypoxemic respira-
tory failure, but the OI has become preferred in 
contemporary pediatric critical care practice, as it 
incorporates the mean airway pressure (MAwP) 
required to maintain oxygenation goals [15]. 
Over the past decade, many retrospective and 
prospective studies have demonstrated an asso-
ciation between higher OI and mortality in chil-
dren with hypoxemic respiratory failure [16–19]. 
Historically, an OI of greater than 20 has been 
used as an indication to transition from conven-
tional mechanical ventilation to high-frequency 
oscillatory ventilation (HFOV) [20, 21]. In these 
studies, an OI greater than 20 is associated with 
mortality rates of more than 40%. The trend in OI 
value is likely more informative than any single 
data point, as pARDS is an evolving disease pro-
cess. For example, utilizing data from preexisting 
cohorts with pARDS, the Pediatric Acute Lung 
Injury Consensus Conference evaluated the fol-
lowing variables as predictors of mortality: initial 
PF ratio, initial OI, worst PF ratio during the first 
3 days of mechanical ventilation, and worst OI 
values during the first 3 days of mechanical ven-
tilation. The worst (highest) OI value during the 
first 3 days of ventilation was the best discrimina-
tor for non-survival, with an area under the 
receiver operating characteristic curve of 0.75 
[15]. Recent data suggests that incorporating an 
inflammatory cytokine profile alongside the oxy-
genation index is superior in predicting outcomes 
in pARDS compared to the oxygenation index 
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alone [22]. These data are intriguing, as they sug-
gest the possibility of a future biomarker array 
that could help identify patients with pARDS at 
risk for mortality and thus stratify those candi-
dates who should be considered for earlier 
ECMO support. Until then, it can be concluded 
that for patients with pARDS that progress to 
ECMO, higher pre-ECMO oxygenation index is 
at higher risk of mortality [23, 24].
Currently, the Extracorporeal Life Support 
Organization recommends an OI sustained above 
40 as the indication for initiation of ECMO in 
children with respiratory failure [25]. However, 
there are likely children with hypoxemic respira-
tory failure and OI values below this threshold 
that could benefit from ECMO’s potential ability 
to mitigate further VILI.  For example, in an 
 analysis of a cohort of children in our institution 
with hypoxemic respiratory failure who were 
ventilated with HFOV, an OI greater than 25 at 
48 h following the onset of pARDS conferred a 
significantly higher odds of mortality (odds ratio: 
5, 95% CI 1.3 to 16.7, p < 0.05) [19]. While the 
predictive value of the oxygenation index contin-
ues to grow in the arena of pediatric critical care, 
to date, no definitive OI threshold exists above 
which pediatric intensivists can be 100% certain 
regarding the optimal time point for the initiation 
of ECMO for pARDS. The Pediatric Acute Lung 
Injury Consensus Conference from 2015 states 
that “it is not possible to apply strict criteria for 
the selection of children who will benefit from 
ECMO in pARDS” [26].
In the absence of strict numerical criteria sur-
rounding oxygenation, intensivists are left to rely 
on the gestalt clinical picture when deciding upon 
the initiation of ECMO to support children with 
hypoxemic respiratory failure. Key components 
within this framework include trends in ventilator 
support and oxygenation measures over time, 
hemodynamic stability, organ function, and acid- 
base status. First, with regard to the trajectory of 
respiratory support and oxygenation, serial 
assessments serve more valuable than an evalua-
tion at a single time point [26]. It is our practice 
to obtain arterial blood gases and calculate the 
oxygenation index every 4  h. Concurrently, we 
also track trends in peak inspiratory pressures as 
a marker for the potential of evolving 
 ventilator- induced lung injury. Second, children 
with evolving hypoxemic respiratory failure can 
develop hemodynamic instability. Etiologies for 
this instability can be multifactorial, including 
impaired oxygen delivery to the myocardium, 
impaired right ventricular preload from increased 
intrathoracic pressure, increased right ventricular 
afterload from hypercarbia and acidosis, and con-
current sepsis. Next, the cascade of inflammatory 
cytokines released during ARDS as well as with 
VILI has been demonstrated to result in direct 
organ dysfunction, fluid retention, and subse-
quent fluid overload [27]. All of the above factors 
may culminate in a progressive metabolic acido-
sis, the effect of which is noteworthy in critically 
ill children. In a retrospective cohort of children 
with hypoxemic respiratory failure supported 
with HFOV, the presence of a metabolic acidosis 
was independently associated with a higher risk 
of mortality [19]. Likewise, studies examining 
pre-ECMO variables in this patient population 
have shown that the presence of acidosis is asso-
ciated with worse survival [23, 24]. For example, 
in a study by Dimico and colleagues containing 
data from 1325 children within the ELSO regis-
try, odds of survival to hospital discharged 
increased by 15% for every 0.1 increase in pre- 
ECMO pH.
 Hypercarbic Respiratory Failure
Though severe refractory hypoxemia is the most 
common indication for pediatric respiratory 
ECMO, there are patients who require ECMO 
due to severe ventilation impairment leading to 
hypercarbia. Acute hypercarbic respiratory fail-
ure is defined as a PaCO2 greater than 50 mmHg, 
typically associated with respiratory acidosis. 
Modern ventilation strategies are focused on lim-
iting VILI and allowing for permissive hypercar-
bia [28, 29]. The possible detrimental effects of 
moderate hypercarbia (50–75 mmHg) have been 
debated, but they are inconsequential compared 
to the risks associated with ECMO [30]. Thus, 
ECMO is not advised for moderate hypercarbia 
(i.e., PaCO2 up to 75 mmHg). However, as PaCO2 
rises and respiratory acidosis becomes more 
severe, dysfunction of other organ systems 
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becomes more significant, particularly that of the 
cardiovascular system. Therefore, severe hyper-
carbic respiratory failure with acidosis and hemo-
dynamic instability is an indication for initiation 
of ECMO [30]. ECMO can correct hypercarbia 
rapidly with a resultant improvement in acidosis 
and organ function. During this process, clini-
cians must be aware of possible detrimental con-
sequences of rapid correction of PaCO2, which 
includes cerebral vasoconstriction and the devel-
opment of alkalosis.
Status asthmaticus is the most common dis-
ease causing severe hypercarbia requiring 
ECMO, but patients with status asthmaticus only 
represented 3% of the pediatric respiratory cases 
reported to ELSO from 2009 to 2015 [31, 32]. 
Patients who require ECMO for status asthmati-
cus typically have severe acidosis (pH < 7.0) and 
severe hypercarbia (PaCO2 > 100 mmHg) despite 
maximal medical therapies [32]. Children with 
status asthmaticus on ECMO have very good sur-
vival, with 88% surviving to hospital discharge. 
Moreover, status asthmaticus improves relatively 
quickly, with an average duration of ECMO of 
92 h [32].
Cystic fibrosis (CF) with pulmonary exacer-
bation is another patient population that can 
require ECMO for severe hypercarbic respiratory 
failure. There were 73 ECMO runs in the ELSO 
registry for cystic fibrosis from 1998 to 2013, 
with 52% survival [33]. There has been debate if 
patients with CF are candidates for ECMO due to 
the progressive nature of their disease. Each 
patient must be evaluated individually. First, the 
reversibility of their respiratory failure should be 
assessed. The primary determination in this 
regard is if the child has a pulmonary infection 
that is potentially amenable to antibiotic therapy. 
If lung disease is not thought to be reversible, 
then candidacy for lung transplantation should be 
considered. Cystic fibrosis should only be con-
sidered an absolute contraindication to ECMO if 
the patient is deemed not to have the potential for 
recovery from the acute process and is not a can-
didate for lung transplantation. Candidacy should 
be considered for any intubated cystic fibrosis 
patient to help inform decisions of whether or not 
to pursue ECMO.  This candidacy should be 
determined by working with your local 
 pulmonologist and, if necessary, a regional lung 
transplant center.
 Airway Disorders
Patients with significant air leaks may not meet 
typical oxygenation or ventilation criteria for 
ECMO. Indications for ECMO support in patients 
with air leak syndromes include recurrent pneu-
mothoraces causing life-threatening events or 
persistent air leaks not improving with chest tube 
thoracostomy. Patients with broncho-pleural fis-
tulae from pulmonary infection or surgery that do 
not heal spontaneously on mechanical ventilation 
can also be successfully managed with ECMO, 
which allows for reduction of peak airway pres-
sure [34, 35]. ECMO can also be used intraopera-
tively for major airway surgeries and 
postoperatively to allow for healing of surgical 
sites without the effects of high positive airway 
pressures [36, 37].
Our recommendations are a general frame-
work to utilize when deciding upon ECMO sup-
port for children with refractory respiratory 
failure who have a potentially reversible lung dis-
ease and no absolute contraindication to ECMO 
(Table 2.1).
Case Presentation
OI was calculated to be 36 without 
improvement over 12  h despite medical 
therapy and use of high-frequency oscilla-
tory ventilation. Her inspired oxygen con-
centration could not be weaned below 
70%. At this point, her refractory hypox-
emic respiratory failure secondary to influ-
enza and Staphylococcus aureus 
pneumonia was considered refractory to 
conventional therapy with no trajectory of 
improvement. There was also concern that 
her potentially injurious ventilator support 
and high inspired oxygen concentration 
would continue to worsen her underlying 
lung disease. Based on these data, cannu-
lation for ECMO was being considered.




Critically ill children may develop respiratory 
failure from a wide array of infectious or nonin-
fectious and direct or indirect etiologies [38]. 
Successful use of ECMO support for children 
with refractory lung injury from a broad variety 
of noninfectious causes has been reported, 
including burn injuries [39], trauma [40, 41], 
hydrocarbon aspiration [42], and rheumatologic 
diseases [43, 44]. In an analysis of factors associ-
ated with pediatric ECMO survival, Zabrocki 
et  al. reviewed 3213 children supported with 
ECMO for a primary pulmonary indication from 
the years 1993 through 2007 [24]. In this review, 
diseases associated with the best survival rates 
include asthma (83%), aspiration pneumonia 
(71%), and RSV bronchiolitis (70%). As infec-
tion is the most common etiology of pARDS 
[45], the remainder of the focus in this section 
will be on specific infectious pathogens. Overall 
survival for children with bacterial and viral 
pneumonia who require ECMO is approximately 
56–59% [24]. Infectious agents that portend 
worse outcomes include Bordetella pertussis, 
herpes simplex virus (HSV), fungal pneumonia, 
and methicillin-resistant Staphylococcus aureus 
(MRSA).
Over the past two decades, the overall survival 
for children with pertussis who are supported 
with ECMO is 39%, considerably lower as com-
pared to children requiring ECMO for other viral 
and bacterial etiologies [24]. In a retrospective 
analysis, children with pertussis who survived 
their ECMO course were found to have higher 
pre-ECMO PEEP (11  cmH2O vs. 7  cmH2O, 
p  =  0.006) and significantly higher pre-ECMO 
pH values (7.31 vs. 7.14, p 0.002) when com-
pared to non-survivors [46]. Lung pathology 
obtained from young infants who died from ful-
minant pertussis shows necrotizing bronchiolitis 
with necrosis of the alveolar epithelium [47]; 
thus, an open-lung strategy achieved with high 
PEEP (i.e., 10–11 mmHg) may help to offset the 
pathophysiologic ramifications of this process. 
Refractory pulmonary hypertension and severe 
leukocytosis are two additional pathophysiologic 
mechanisms which contribute to the severity of 
fulminant pertussis infections. Significantly leu-
kocytosis is observed in infants with the most 
severe infections, with white blood cell (WBC) 
counts in excess of 100,000/mm3 associated with 
increased mortality risk [48]. Postmortem exami-
nations of these patients show leukocytes 
obstructing the pulmonary blood vessels [47]. 
This severe leukocytosis leads to vascular hyper-
viscosity and pulmonary arteriole thromboses 
and, when combined with the reactive pulmonary 
vasculature of the young infant, pulmonary 
hypertension refractory to conventional therapy. 
Given the role of leukocytosis in the pathology of 
this disease, an interesting single-center case 
series explored the utility of leukodepletion in 
infants with fulminant pertussis [49]. 
Implementation of a clinical protocol for leu-
kodepletion for children with WBC count of 
greater than 50,000/mm3 resulted in improved 
survival, with a reduction in mortality from 44% 
to 10%. Leukofiltration for patients receiving 
ECMO support was accomplished by placing a 
WBC filter sited in the bridge of the ECMO cir-
cuit. While this report was a single-center study 
with a small volume of patients, a case-mix 
adjustment accounting for age, WBC count, and 
ECMO referral time revealed a significantly bet-
ter observed mortality following the implementa-
tion of leukodepletion than predicted. Thus, 
while the prognosis for infants with fulminant 
pertussis requiring ECMO remains guarded, 
implementation of leukodepletion can be consid-
ered to help offset the pathologic consequences 
of severe leukocytosis and subsequent pulmonary 
hypertension.
Case reports exist which describe the use of 
ECMO to support both neonates [50] and adults 
[51] for HSV infections. ECMO was successful 
in the cases of isolated respiratory infection lead-
ing to ARDS. Conversely, the outcomes for use 
of ECMO with disseminated HSV infection 
remain quite poor. Disseminated neonatal HSV is 
a rapidly progressive infection, which leads to 
multiple organ failure and has a high mortality 
rate despite aggressive care. A 2010 review of 40 
neonates with HSV infection supported with 
M. Friedman and M. Hobson
23
ECMO showed an overall survival to hospital 
discharge of 25% [52]. Survival remained con-
stant across all decades, suggesting that the ful-
minant nature of this particular infection should 
cause one to approach initiating ECMO with 
caution.
Patients with active fungal infections prior to 
the initiation of ECMO are at risk of persistent 
seeding and contamination of the ECMO circuit. 
Candida was the predominate fungal species 
acquired both pre- and during ECMO in a study 
of the ELSO registry. While the presence of a 
fungal infection significantly increased the odds 
of mortality in all age groups, 82–89% of patients 
with fungal infections prior to the initiation of 
ECMO became culture negative at some point 
into their ECMO course [53]. Similarly, the pres-
ence of a fungal infection did not lead to an 
increase in circuit complications or circuit fail-
ure. Thus, the authors of this review concluded 
that while a fungal infection remains an  important 
comorbidity to consider when initiating ECMO 
support, it, in and of itself, should not be consid-
ered an absolute contraindication to 
ECLS.  However, caution must be exercised for 
pediatric patients with respiratory failure second-
ary to fungal infections. In the aforementioned 
review by Zabrocki et al., fungal pneumonia was 
the single diagnosis independently associated 
with the highest risk of mortality [24]. It is likely 
that the fungal infection alone does not portend to 
a grim prognosis but rather is a surrogate marker 
for patients with other diagnoses associated with 
poor outcomes on ECMO, such as patients with 
oncological diagnoses.
Community-acquired MRSA is an invasive 
bacterium that can cause skin and soft-tissue 
infections in previously healthy children. The 
invasive nature of this bacterium may lead to 
severe necrotizing pneumonia and ARDS in 
some children. Concurrent with the rise of inva-
sive MRSA infections in the community over the 
past 25 years, the use of ECMO to support chil-
dren with hypoxemic respiratory failure second-
ary to MRSA pneumonia has also risen [54]. 
Mortality from this pathogen remains high, with 
an approximate mortality rate of 50% for chil-
dren who require ECMO; children older than 5 
years seem to be particularly at risk. MRSA 
pneumonia and sepsis may result in 
thrombocytopenia- associated multiple organ fail-
ure (TAMOF), and there is some evidence which 
shows benefit from plasmapheresis performed 
during ECMO to reverse the sequelae of this dis-
order [55]. Combining plasmapheresis to the 
ECMO circuit adds a layer of technical complex-
ity, and there is also increased heparin clearance 
during the procedure, thus necessitating careful 
monitoring of anticoagulation. Despite these 
challenges, recent data have shown that therapeu-
tic plasma exchange can improve organ function 
in children with sepsis-induced multiorgan dys-
function who require ECMO support [56].
 Duration of Mechanical Ventilation
As late as the 1990s, children with respiratory 
failure were not considered candidates for extra-
corporeal support after 7–10 days of mechanical 
ventilation due to a significant reduction in sur-
vival when ECMO was initiated beyond this 
timeframe [57, 58]. In this era, lung-protective 
ventilator strategies had not yet become standard 
practice, and, perhaps, significant VILI that had 
accrued in these children prior to ECMO initia-
tion was irreversible. More contemporary data 
suggests that the optimal timing for ECMO initi-
ation still lies within the first week of mechanical 
ventilation [59–61], but outcomes for children 
ventilated beyond 7  days prior to ECMO have 
improved such that these children should still be 
considered appropriate candidates for extracor-
poreal support. Domico et al. reviewed the rela-
tionship of pre-ECMO mechanical ventilation 
duration and the outcomes of 1352 pediatric 
patients who required ECMO for respiratory fail-
ure from 1999 to 2008 [23]. In this analysis, a 
significant reduction in survival was not observed 
until the pre-ECMO duration of ventilation 
exceeded 14 days. Similarly, in Zabrocki’s review 
of pediatric respiratory failure, analysis of pre- 
ECMO mechanical ventilation revealed that sur-
vival remained 56% or higher for children who 
had ECMO initiated within the first 14 days of 
mechanical ventilation but declined to 38% 
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beyond this timeframe [24]. Fourteen days is now 
often considered a “cutoff” for duration of venti-
lation prior to ECMO; however, the outcomes for 
patients with certain diagnoses, such as viral 
pneumonia, can be good even when ECMO is 
initiated after 2 weeks of ventilation [21, 22]. 
Careful patient selection is therefore paramount 
to successful use of when ECMO if extracorpo-
real support is initiated after an extended course 
of mechanical ventilation. Factors that should be 
considered are the number of comorbidities, the 
number of non-pulmonary organ failures, and the 
primary cause of pARDS.
 Patient Comorbidities
Historically, the ideal ECMO candidate was one 
with a known reversible illness, had single-organ 
failure and minimal comorbidities, was neuro-
logically intact and not developmentally delayed, 
and had minimal bleeding risk. Practically speak-
ing, very few children cared for in modern-day 
pediatric intensive care units fit this description. 
Over the past two decades, the use of ECMO for 
respiratory support in children with comorbidi-
ties has increased markedly. In 1993, 19% of 
children placed on ECMO had underlying comor-
bidities, compared to 47% in 2007 [24]. Not sur-
prisingly, children with comorbidities have lower 
survival rates when compared to previously 
healthy children [24]. Comorbidities which have 
been shown to significantly increase mortality on 
ECMO include acute kidney injury, liver failure, 
cancer, primary immunodeficiency, and pre- 
ECMO cardiac arrest [24].
Acute kidney injury is a common occurrence 
in the intensive care setting, and its impact on 
outcomes of children requiring ECMO is notable. 
Recently, the Kidney Intervention During 
Extracorporeal Membrane Oxygenation Study 
Group showed that approximately 60% of chil-
dren requiring ECMO support have acute kidney 
injury, and this comorbidity is associated with a 
longer duration of ECMO and an increased risk 
of mortality [62]. Closely related to acute kidney 
injury is fluid overload, which also impacts 
ECMO patient outcomes. In a recent analysis of 
756 neonatal and pediatric ECMO patients, peak 
fluid overload, fluid overload at ECMO discon-
tinuation, and the change in fluid overload during 
ECMO were significantly higher in patients who 
suffered mortality either while on ECMO or later 
during their hospitalization [63].
The status of a patient’s immune system is a 
significant consideration when deciding upon a 
child’s suitability for extracorporeal support. 
Historically, an immunocompromised condition 
was a relative contraindication for ECMO for 
several reasons:
• Leukopenia from chemotherapy or the disease 
process itself confers a risk for subsequent 
super-infection.
• Concurrent thrombocytopenia and coagulopa-
thy place patients at a higher risk for hemor-
rhagic complications.
• Multiorgan failure is often present prior to the 
initiation of ECMO.
• Doubt or uncertainty may exist regarding the 
patient’s long-term prognosis with respect to 
their underlying disease.
A recent review examined the outcomes of 
107 children with underlying malignancies (73 
hematologic, 34 solid tumors) who received 
ECLS for various disease processes (the majority 
of which were acute respiratory failure) over a 
13-year period [64]. Overall survival to hospital 
discharge was 35% (36% for respiratory failure, 
29% for cardiac failure), which is worse than for 
other children receiving ECLS.  Despite their 
immunosuppressed state, only 19% of these chil-
dren acquired a new infection while on 
ECMO.  Children with malignancies did have a 
higher rate of hemorrhagic complications, includ-
ing cannula site bleeding, disseminated intravas-
cular coagulation, and CNS hemorrhages when 
compared to children without cancer. Currently, 
most pediatric ECMO centers offer ECMO sup-
port for this patient population. Of 118 centers 
surveyed, 78% did not view the presence of a 
malignancy as a contraindication, and 17% con-
sidered pediatric cancer as only a relative contra-
indication to ECMO [64]. The support for the use 
of ECMO in this patient population, despite only 
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a 35% overall survival, likely stems from the 
notion that these patients, the majority of whom 
have leukemia, have a good prognosis with regard 
to their underlying malignancy if their acute 
respiratory failure can be overcome. In this 
cohort, the median OI prior to initiation of ECMO 
was 52, reflecting that these patients likely have a 
higher degree of lung injury prior to ECMO ini-
tiation, relative to other patient populations. It 
remains to be seen if earlier initiation of ECMO 
within this patient population could potentially 
result in improved outcomes. Regardless, malig-
nancy should not be considered an absolute 
 contraindication from ECMO.  Close communi-
cation with the child’s oncology team regarding 
the long-term prognosis from their underlying 
malignancy is an additional essential piece of 
information to be considered in this decision-
making process.
Children undergoing hematopoietic stem cell 
transplantation (HSCT) are another immunosup-
pressed patient population where the decision to 
implement extracorporeal support may be con-
troversial. These children can develop life- 
threatening complications in the immediate 
posttransplant period (e.g., diffuse alveolar hem-
orrhage, idiopathic pulmonary syndrome, various 
infections) and in the later stages following trans-
plantation (e.g., graft versus host disease, bron-
chiolitis obliterans), all of which can lead to 
respiratory failure refractory to conventional 
care. Historical mortality rates for children 
requiring mechanical ventilation following 
HSCT are well over 50% [65–67]. More recent 
data suggests that an earlier transition from con-
ventional ventilation to HFOV may improve sur-
vival, but mortality remains high [68]. With 
regard to the use of ECMO in this patient popula-
tion, there are sparse case reports documenting 
the successful use of ECMO to support HSCT 
patients through posttransplant complications, 
including diffuse alveolar hemorrhage, [69] idio-
pathic pulmonary syndrome, [70] and sepsis sec-
ondary to neutropenic enterocolitis [71]. 
However, in an ELSO registry review of 19 chil-
dren undergoing ECLS following HSCT, 79% 
died during the ECMO course: seven developed 
multiorgan failure, three had refractory hemor-
rhage, and five had support was withdrawn for 
others reasons [72]. Furthermore, only one of the 
four remaining children alive after ECMO sur-
vived to hospital discharge. A more recent ELSO 
registry review of children placed on ECMO sup-
port following hematopoietic stem cell transplant 
also showed poor outcomes, with only 10% of 
patients surviving to hospital discharge [73]. 
Based on this experience, it can be concluded 
that, at the present time, children undergoing 
HSCT are unlikely to survive refractory respira-
tory failure requiring ECMO. Broadly speaking, 
this population of children has had dismal out-
comes when requiring intensive care admission, 
particularly if mechanical ventilation is neces-
sary, and thus ECMO should be avoided.
In summary, while the historical approach 
may have been to reserve ECMO for previously 
healthy “salvageable” patients, contemporary 
ECMO utilization has shown that there are in fact 
very few conditions completely incompatible 
with ECMO.  In the setting of pediatric respira-
tory failure, extracorporeal support serves as 
either a bridge to patient recovery or a bridge to 
consideration for lung transplantation in the event 
of non-recovery. Unless a disease process is 
deemed irreversible or the child is not a candidate 
for lung transplantation, ECMO remains a realis-
tic option to support most critically ill children 
with refractory respiratory failure.
 ECMO Modality and Cannulation 
Strategy
Once the decision has been made to initiate extra-
corporeal support for the child with worsening 
respiratory failure, the next determination is 
choice of ECMO modality. Venovenous (V-V) 
ECMO involves the removal of deoxygenated 
blood from the patient’s right atrium, oxygen-
ation and ventilation as the blood traverses 
through the ECMO circuit, and then return of 
oxygenated blood into the child’s central venous 
circulation through a different port, often within 
the same cannula. V-V ECMO provides gas 
exchange but no direct cardiac support. In con-
trast, with veno-arterial (V-A) ECMO, oxygen-
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ated blood returning to the patient enters the 
arterial circulation, commonly through a differ-
ent cannula in the carotid or femoral artery. 
Completely bypassing the patient’s native heart 
and lungs, V-A ECMO can provide complete car-
diopulmonary support [74].
The inherent risks between these two ECMO 
modalities should be considered. With V-A 
ECMO, cannulation of the femoral artery incurs 
the risk of lower extremity ischemia [74], while 
cannulation of the carotid artery carries a sub-
stantial risk of stroke (23%) [75]. In an analysis 
of pediatric patients with respiratory failure, 
the use of V-A ECMO was independently asso-
ciated with an increased risk of neurologic 
injury when compared to V-V ECMO [76]. 
Other risks associated with V-A ECMO include 
embolism of air or thrombi into the patient’s 
arterial circulation or increased systemic after-
load leading to distension of the left ventricle, 
with subsequent risk of pulmonary hemorrhage. 
The primary disadvantage of V-V relative to 
V-A ECMO is its inability to provide cardiac 
support for patients with hemodynamic insta-
bility. However, there are important cardiac 
benefits that indirectly result from initiation of 
V-V ECMO for respiratory failure. First, with 
the ability to wean mechanical ventilation, 
intrathoracic pressure decreases, thereby 
improving preload to the right ventricle. 
Second, the ability of V-V ECMO to correct 
hypercarbia and acidosis can lead to a reduction 
in pulmonary vascular resistance and a corre-
sponding decrease in right ventricular after-
load. Lastly, oxygenated blood returning from 
the ECMO circuit passes through the pulmo-
nary vasculature, eventually making its way 
into the left ventricle. A portion of this blood 
will enter the coronary circulation as it exits the 
aortic valve, providing a previously oxygen-
deprived myocardium with a rich source of 
oxygen and a resultant improvement in ventric-
ular function and hemodynamics.
In a single-center review of children requiring 
ECMO for acute respiratory failure from 1991 
through 2002, Pettignano et  al. illustrated the 
hemodynamic benefits of V-V ECMO [77]. In 
this cohort, 35% of patients required at least one 
vasopressor, and 41% required at least one ino-
tropic infusion at the time of ECMO cannula-
tion. After initiation of ECMO support, there 
was a significant reduction in vasoactive medica-
tion requirements, and all patients were free 
from vasoactive infusions by day 6 of 
ECMO.  Similarly, an analysis of 4332 ECMO 
runs for children with sepsis showed signifi-
cantly better survival for children receiving V-V 
support when compared to those on V-A ECMO 
[78]. This study was unable to account for pre-
ECMO severity of illness and also did not factor 
in the type of hemodynamic derangement that 
characterized each patient’s type of sepsis (i.e., 
warm shock vs. cold shock). However, the fact 
that such a large number of children with sepsis 
were successfully supported with V-V ECMO 
gives credence to the ability of this modality to 
support critically ill children who have unstable 
hemodynamics.
The use of V-V ECMO in pediatric critical 
care is continuing to increase [79], and based on 
data from a large retrospective review, V-V 
ECMO appears to confer a survival advantage 
relative to V-A ECMO [24]. To date, there is no 
definitive formula or inotrope score by which to 
guide intensivists in choice of ECMO modality 
for children with acute respiratory failure and 
associated hemodynamic instability. Our own 
institutional practice relies greatly on echocar-
diogram imaging of myocardial performance to 
aid in this decision. A child with mild to moder-
ately depressed right ventricular function, which 
is most often due to a combination of high pul-
monary vascular resistance induced by lung dis-
ease and respiratory acidosis, is a candidate for 
V-V ECMO, even if requiring a moderate amount 
of vasoactive medications for hemodynamic sup-
port. V-V ECMO is recommended for these 
patients, even in the setting of hemodynamic 
instability, as correction of respiratory acidosis 
and an increase in right ventricular preload that 
occur after ECMO initiation often improve ven-
tricular function. In contrast, a child with an 
echocardiogram showing significantly depressed 
left ventricular or biventricular function due to 
sepsis-induced myocardial depression should be 
cannulated for V-A ECMO.
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ECMO cannula selection and configuration is 
an essential decision made in the process of initi-
ating V-V ECMO support. One option for V-V 
cannulation is a multisite configuration with 
single- lumen ECMO catheters, the first being 
placed within the right internal jugular vein and 
extending into the right atrium and the second 
inserted into a femoral vein and extending 
upward into the inferior vena cava. The alterna-
tive cannulation option utilizes a dual-lumen 
venovenous (VVDL) catheter inserted into the 
right internal jugular vein, with both drainage 
and reinfusion lumens of the cannula residing 
within the right atrium. One disadvantage of the 
two-cannula technique includes the need to 
access multiple venous sites, thus being a more 
invasive and time-consuming procedure, along 
with increasing the sites for potential bleeding 
and infectious complications. Second, children 
weighing less than 15 kg typically do not have 
large enough femoral veins to accommodate the 
necessary-sized ECMO catheters. Given these 
constraints of the two-site cannulation technique, 
the application of the VVDL cannulation strategy 
to provide ECMO support to children with respi-
ratory failure has increased significantly over the 
past decade [24, 80]. Zamaro et al. analyzed the 
performance and complication rates of these two 
cannulation strategies from 1323 pediatric V-V 
ECMO runs [80]. Compared to multisite cannu-
lation, VVDL cannulation achieved greater 
weight-adjusted ECMO flow but had a slightly 
higher rate of mechanical (26.2% vs. 22.5%, p 
0.004) and cardiac (24.4% vs. 21.7%, p 0.03) 
complications. Importantly, there was no signifi-
cant difference in survival between the two can-
nulation techniques.
One drawback to early versions of VVDL 
ECMO catheters was their potential to bend and 
kink, thus raising the possibility of obstruction 
to blood flow and interruption of the ECMO cir-
cuit. The newer generation of VVDL catheters 
is manufactured with wire reinforcement to off-
set this potential complication. The only avail-
able pediatric literature comparing these two 
types of catheter designs was a single-center 
retrospective study of 25 neonates and infants, 
which found no difference in the incidence 
ECMO flow interruption between the wire-rein-
forced and non-wire cannulas within the first 
72  h [81]. The two wire- reinforced VVDL 
ECMO catheters currently available for pediat-
ric use are the OriGen® DL cannula (OriGen® 
Biomedical, Austin, TX) and Avalon® Elite 
Bicaval cannula (Avalon® Laboratories, LLC, 
Rancho Dominguez, CA). The OriGen® is 
placed in the right atrium and has a proximal 
drainage hole and distal reinfusion hole. The 
configuration of the bicaval Avalon® cannula 
places the drainage holes within the SVC and 
IVC, while the reinfusion port is located within 
the right atrium and is directed toward the tri-
cuspid valve, offering the theoretical advantage 
of reducing the amount of recirculation. The use 
of bicaval ECMO cannulas has been shown to 
be effective and safe in the adult ECMO popula-
tion [82, 83], but the smaller- sized venous and 
cardiac structures inherent to pediatric patients 
may raise concern regarding an increased rate of 
mechanical complications and increased need 
for catheter repositioning. Several pediatric 
ECMO centers have published their institutional 
experiences with the bicaval wire- reinforced 
cannulas and have noted minimal complications 
in both pediatric and neonatal patients [81, 84–
86]. In an analysis of cannula complications by 
Zamaro and colleagues, there was no difference 
in rate of complications when wire-reinforced 
and non-wire-reinforced catheters were com-
pared [80]. Proper imaging techniques during 
cannulation, including the combined use of 
echocardiography and fluoroscopy, have been 
shown to reduce complications and the need for 
catheter repositioning [86]. Lastly, successful 
and safe percutaneous ECMO cannulation of 
pediatric patients performed by intensivists has 
recently been described [87]. A single-center 
retrospective review of percutaneous ECMO 
cannulations performed by intensivists included 
18 pediatric patients cannulated for V-V 
ECMO.  In this cohort, the overall rate of suc-
cessful cannulation was 98% [87]. In our cur-
rent practice, we consider wire-reinforced 
VVDL ECMO catheters safe for pediatric 
patients and are the preferred modality by which 
to provide extracorporeal respiratory support.




There have been major strides in the study of 
mechanical ventilation in ARDS over the past 
decades [29]. The result of these studies has been 
the low tidal ventilation strategy, which consists 
of low tidal volumes (VT) (6–8  mL/kg), PEEP 
titrated to keep FiO2 < 0.6, and permissive hyper-
carbia. However, for patients who fail this strat-
egy and are cannulated for ECMO, the optimal 
ventilator management strategy has not been well 
studied. The ideal mechanical ventilation strat-
egy would limit VILI without lengthening ECMO 
duration due to lung collapse.
Traditional ventilator management on ECMO 
has been a “lung-rest” strategy to limit 
VILI. Current ELSO guidelines suggest low rate, 
moderate PEEP (5–15 cmH2O) and low plateau 
pressure [25]. Few published studies describe 
mechanical ventilation practices while on ECMO 
in the pediatric population. A recent survey found 
most pediatric intensivists (87%) employ a strat-
egy of “lung rest” while on ECMO [88].
According to a recent review, most adult 
patients have VT, FiO2, and plateau pressure sig-
nificantly reduced after initiation of ECMO, 
while PEEP is minimally reduced from their pre- 
ECMO support, being maintained on average 
between 12 and 13 cmH2O [89]. In this review, 
the proportion of patients with ventilator settings 
considered to be injurious (defined as TV > 8 mL/
kg, plateau pressure > 30 cmH2O, peak inspira-
tory pressure >35 cmH2O or FiO2 ≥ 0.8) decreased 
from 90% pre-ECMO to 18% after initiation of 
ECMO [89].
The goal of the historical practice of “lung 
rest” is to limit the risk of VILI, but this strategy 
often leads to lung collapse. In a recent survey of 
mechanical ventilation practices during ECMO, 
most pediatric intensivists (76%) target a PEEP 
of ≤10 cmH2O [88]. This level of PEEP in the 
setting of pARDS will frequently lead to total 
lung collapse and the need for re-recruitment of 
the lung later in the ECMO course. The need for 
re-recruitment may prolong the ECMO course 
and contribute to VILI. Given this concern, some 
intensivists no longer practice strict “lung rest” 
while on ECMO for ARDS [90]. The most popu-
lar new ventilation practice is an open-lung strat-
egy on ECMO, similar to the adult ARDS low VT 
ventilation strategy [91].
While attempting aggressive lung recruitment 
in the acute inflammatory stage of ARDS is dis-
couraged, as it can exacerbate VILI, maintaining 
lung recruitment with relatively high MAwP 
while on ECMO may be advisable. On conven-
tional ventilation, this goal is achieved by main-
taining high PEEP with a long inspiratory time. 
Airway pressure release ventilation (APRV) is a 
mode of ventilation, which utilizes a high dis-
tending pressure with brief intermittent releases 
of pressure to improve ventilation, and patients 
are able to spontaneously breathing during the 
periods of high distending pressure [92]. APRV 
can also be used to achieve a high MAwP without 
high plateau pressures, similarly to a high PEEP 
and long inspiratory time strategy with conven-
tional ventilation, which maintains recruitment 
with potentially less risk of VILI. The ELSO rec-
Case Presentation
In addition to her persistently elevated OI, 
her relatively short duration of illness thus 
far and her potentially reversible viral 
influenza and Staphylococcus aureus pneu-
monia were determined to be characteris-
tics of a good candidate for ECMO.  The 
patient was receiving relative modest doses 
of vasoactive support  – epinephrine 
0.06 mcg/kg/min and dopamine 5 mcg/kg/
min. These infusions were likely necessary 
due to the combination of hypoxemia, 
respiratory acidosis, and high MAwP, con-
ditions that were considered amenable with 
venovenous ECMO.  The decision was 
therefore made to cannulate the patient 
with a wire-enforced VVDL cannula in her 
right internal jugular vein for V-V ECMO 
support. Following successful cannulation, 
vasoactive medications were able to be 
easily weaned to off over the first 12 h on 
ECMO.
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ommendations regarding PEEP offer a wide 
acceptable range – 5–15 cmH2O [25]. The use of 
PEEP at the higher end of this range in neonates 
with respiratory failure has been shown to lead to 
shorter duration of ECMO [93, 94]. Similarly, in 
adults on V-V ECMO, higher PEEP during the 
first 3 days on ECMO has been associated with 
improved survival [95]. Conversely, higher PEEP 
over the whole ECMO course has been shown to 
be associated with increased mortality [96]. It is 
hard to reconcile these seemingly incongruous 
findings. However, one could hypothesize that 
PEEP later in the ECMO course is more related 
to patient factors than ventilator strategy. In other 
words, patients with improving lung disease will 
have PEEP decreased over the course on ECMO, 
while patients who do not improve and ultimately 
die will remain on higher PEEP throughout their 
course. Additionally, high PEEP in the first 
3 days on ECMO is more likely to be a conscien-
tious strategy of maintaining lung recruitment 
and less so reflective of the patient’s severity of 
lung disease.
The risks of maintaining a higher MAwP must 
be weighed against the risks of allowing lung 
 collapse. High MAwP will cause elevated intra-
thoracic pressure which may impair hemody-
namics due to impaired venous return. Elevated 
static pressures, like those used in an open-lung 
ventilation strategy or in APRV, do not to contrib-
ute significantly to VILI [97]. There are also risks 
to a lung-rest approach resulting in complete 
lung collapse. Hemodynamically, lung collapse 
will lead to increased right ventricular afterload 
by way of increased pulmonary vascular resis-
tance. On V-V ECMO, lung collapse will also 
lead to severe pulmonary venous desaturation, 
and systemic arterial saturations will suffer. 
Additionally, there is emerging evidence of the 
damaging effects of recurrent atelectasis, often 
called atelectrauma [8, 98, 99]. If there is com-
plete lung collapse, the lungs will need to be re-
recruited later in the ECMO course, which often 
can only be accomplished with high driving pres-
sure, which is the biggest contributor to VILI 
[97]. Lastly, the time necessary to re-recruit the 
lungs may prolong the ECMO course. Neonatal 
data shows that higher PEEP (i.e.,12–14 cmH2O 
vs 4–6 cmH2O) leads to shorter ECMO runs and 
fewer complications [93, 94]. Identifying the 
ideal PEEP for a patient is a multifactorial deci-
sion that includes evaluation of lung expansion 
on chest x-ray, hemodynamics, oxygenation, 
lung compliance, and other factors. In a recent 
study, the use of electrical impedance tomogra-
phy for adult patients with respiratory failure on 
ECMO showed that an optimal PEEP of 
15 cmH2O best balanced overdistension and lung 
collapse [100].
The one consistent finding from the limited 
data published about mechanical ventilation for 
adults on ECMO is that higher driving pressure 
(peak inspiratory pressure minus PEEP) or pla-
teau pressure is associated with increased mortal-
ity [89, 101, 102]. Limiting peak or plateau 
pressure is advisable for adults on ECMO as it is 
for any adult with ARDS.  However, the upper 
limit of what is reasonable for driving and pla-
teau pressures in children has not been well 
established in pARDS and might be higher than 
in adults [17, 18, 103].
 Secretion Clearance on ECMO
Invasive procedures on ECMO are avoided when-
ever possible due to the increased risk of hemor-
rhage associated with anticoagulation. 
Bronchoscopy, however, is an invasive procedure 
that may be necessary for some patients sup-
ported on ECMO. Though there are only a few 
reports of bronchoscopy on ECMO in the litera-
ture [98–101], it is commonly implemented in 
clinical practice. Routine bronchoscopy of 
patients on ECMO is performed in 55% of pedi-
atric ECMO centers and 76% of adult centers 
[90]. While the benefits of bronchoscopy on 
ECMO have not been established in the litera-
ture, they are often seen at the bedside in patients 
with thick respiratory secretions that cannot be 
mobilized through traditional suctioning tech-
niques. In the limited published data on pediatric 
bronchoscopies on ECMO to date, minor bleed-
ing episodes occur in up to 35% of patients in 
some report, the risk of significant pulmonary 
hemorrhage is 0–1.5% [104–107]. Bronchoscopy 
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is therefore feasible and relatively safe in patients 
on ECMO, with a small risk of pulmonary 
hemorrhage.
HFPV is a combination of high-frequency 
ventilation and conventional mechanical ventila-
tion principles. HPFV consists of high-frequency 
sub-physiological tidal volumes superimposed 
on low-frequency conventional tidal volume ven-
tilation [108]. One institution published their 
experience with the use of high-frequency per-
cussive ventilation (HFPV) and increased fre-
quency of bronchoscopy to target secretion 
clearance for pediatric respiratory ECMO. They 
showed an increase in ECLS-free days when 
compared to historical controls [106]. It is not 
clear if the benefit was due to HFPV, increased 
bronchoscopies, the combination of the two, or 
other changes to practice that were not measured. 
The use of HFPV and frequent bronchoscopy 
promotes secretion clearance and is most likely 
to be beneficial in diseases that cause excessive 
secretions such as bronchiolitis.
 Extubation on ECMO
The practice of extubation on ECMO has becom-
ing increasingly utilized in the past several years. 
In a 2015 survey, only 10% of centers reported 
extubating patients on ECMO, while a 2017 sur-
vey reported 41% of centers extubate patients 
[90, 91]. ECMO is employed to allow for oxy-
genation and ventilation without the risk of 
VILI.  It has been suggested, therefore, that the 
best way to limit VILI would be to remove the 
“V” or ventilator. Extubating patients on V-V 
ECMO has been shown to be feasible and safe in 
selected patients [90, 109]. In one retrospective 
study, extubation on ECMO was associated with 
improved survival [109]. If extubation is feasible, 
there is the benefit of reducing sedation once the 
noxious stimulus that is the endotracheal tube is 
removed. Patients who are extubated and not 
sedated will also be able to participate in more 
aggressive rehabilitation while on ECMO.  Not 
all patients will be candidates for extubation on 
ECMO.  Younger patients, for instance, may 
require paralysis or heavy sedation to prevent 
mechanical complications, obviating any possi-
bility of extubation. It should also be noted that 
extubated patients might require reintubation for 
procedures including bronchoscopy and decan-
nulation from ECMO.
 Recommendations
Maintenance of lung aeration with modest venti-
lator settings may be advantageous to their recov-
ery. Lung aeration will facilitate higher arterial 
oxygen saturations (SaO2), allow for some oxy-
genation if there is an emergency requiring sepa-
ration from the circuit, and possible shorten 
ECMO course by eliminating the time needed to 
re-recruit collapsed lung. Our usual strategy is to 
maintain lung aeration with high PEEP (10–
14 mmHg) or APRV when possible. Due to our 
concerns that strict adherence to the historical 
“lung-rest” settings with low driving pressure 
(e.g.. 10  cmH2O) and complete lung collapse 
may not be optimal and may prolong the ECMO 
course, we often use slight higher MAwP (15–
20 mmHg) and driving pressure (12–18 mmHg) 
than historical “lung rest.” On the other hand, 
when there is complete lung collapse despite 
these moderate MAwP, we do not advise trying to 
re-recruit alveoli in the acute inflammatory phase 
of pARDS.
Some patients will have complete lung col-
lapse in the face of high MAwP. In patients with 
lung collapse and who are likely to have pro-
longed ECMO courses, extubation is an option. 
Patients that are most likely to be able to be extu-
bated and benefit from extubation are school- 
aged or older children in whom a short ECMO 
run (<7 days) is not expected. Further, to success-
fully extubate patients on ECMO, the circuit 
must be able support oxygenation without the aid 
of mechanical ventilation, which requires high 
flow rates without significant recirculation issues.
We support aggressive airway clearance with 
bronchoscopy for pediatric respiratory ECMO, 
particularly in patients with disease processes 
that lead to mucous plugging. Bronchoscopy is 
likely most beneficial when performed early, 
such as within the first week on ECMO, with the 
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goal of lung recruitment when the inflammatory 
stage of pARDS is resolving. The need for fur-
ther bronchoscopy can be determined by the 
secretion burden noted during the first bronchos-
copy and the subsequent clinical course. 
Diagnostic bronchoscopy can also be performed 
to assess for infectious complications. Routine 
reduction or interruption anticoagulation for 
bronchoscopy is not suggested due to low risk of 
significant bleeding.
 Centralization of ECMO 
and the Effect of Center Volume
The relationship between ECMO volume and 
the quality of ECMO care delivered at individ-
ual centers are active topics of discussion and 
study. There are theoretical benefits of central-
ization of this highly complex care. ECMO is 
relatively rare, even in the largest centers, and 
centralization of care allows for a concentration 
of expertise. ECMO requires a team approach 
between ECMO technicians, bedside nurses, 
respiratory therapists, surgeons, intensivists, 
and other medical personnel. All members of 
the team must have an understanding of the 
special needs of a patient on ECMO.  Centers 
that perform a high volume of ECMO develop 
an institutional knowledge that can only 
develop over many years and many ECMO 
runs.
There have been multiple studies done to 
evaluate if center volumes affect outcomes. 
Children treated at sites with 20–49 ECMO runs 
per year and greater than 50 ECMO runs per 
year (pediatric and neonatal combined) have 
been shown to have lower odds of mortality 
compared to centers with less than 20 runs per 
year [110]. The single cut-point that produced 
the most significant difference in mortality was 
22 cases per year [110]. In another study, there 
was a strong relationship between center volume 
and mortality for pediatric cardiac patients [111]. 
Lastly, when survival was assessed based on 
age-specific center ECMO volumes, neonatal 
and adult volumes were significantly associated 
with survival, and there was a nonsignificant 
trend toward improved survival in higher-vol-
ume centers for pediatric patients [112]. The 
effect of center volume is particularly difficult to 
answer concerning pediatric respiratory 
ECMO.  A medium-to-large sized pediatric 
ECMO program may only have five respiratory 
cases per year, and few centers perform more 
than ten pediatric respiratory ECMO runs annu-
ally. A recent international position paper on 
ECMO for acute respiratory failure in adults 
argues for centralization of ECMO and a mini-
mum of 20 ECMO cases per year, with 12 of 
them being for respiratory support [113]. This 
recommendation is based on the pediatric data 
discussed above and expert opinion.
In the CESAR trial, adult patients with severe 
ARDS were randomized to staying at commu-
nity hospitals or being transferred to a center 
capable of ECMO [5]. Patients who were trans-
ferred had improved survival (63% vs. 47%), 
even though only 75% of transferred patients 
were cannulated for ECMO [5]. Therefore, early 
transfer from centers that do not provide ECMO 
can be recommended for patients with severe 
ARDS with high OI.  Volume alone however 
does not ensure quality care; education,  training, 
Case Presentation
After cannulation for venovenous ECMO, 
the 2-year-old child with influenza and 
Staphylococcus pneumonia was managed 
with a high PEEP strategy 
(i.e.,10–12  mmHg) and modest driving 
pressure (i.e., pressure above PEEP 
12–16 mmHg). Daily chest x-rays demon-
strated modest lung aeration. During the 
initial portion of her ECMO course, she 
was receiving only relatively small tidal 
volumes (~2–3 mL/kg) with this approach. 
Over the next 2 weeks, with the assistance 
of an aggressive pulmonary toilet that 
included multiple bronchoscopies, her tidal 
volumes gradually increased to 6–7 mL/kg, 
and she tolerated weaning of ECMO sup-
port. She was successfully decannulated 
after 20  days of ECMO support with no 
detectable complications.
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and ongoing quality improvement must be com-
bined with clinical expertise. It is recommended 
that all personnel caring for patients on ECMO 
are familiar with the circuit function and poten-
tial complications [26]. Given the relative rarity 
of ECMO, particularly pediatric respiratory 
ECMO, hands-on clinical experience can be 
limited. Simulation is a tool that can increase 
familiarity to ECMO and its complications. 
Simulation has been shown to be a beneficial 
educational tool in ECMO [114, 115]. A simula-
tion program for all personnel caring for ECMO 
patients should be pursued, especially at low-
volume centers, to augment orientation and 
ongoing learning.
In summary, though the minimum number of 
cases needed to provide adequate ECMO care is 
not clear, center volume likely plays a role in the 
quality of ECMO care and outcomes. 
Furthermore, in pediatrics, there may be indica-
tion specific and age specific minimums since 
cardiac, neonatal, and pediatric respiratory 
ECMO have distinct differences that require dif-
ferent knowledge and skill sets. Centralization of 
ECMO is likely beneficial to patients.
 Prolonged ECMO and Lung 
Transplantation
 Long-Term ECMO
The average for duration of ECMO support for 
pediatric respiratory failure is slightly less than 
13  days [1]. However, there are some patients 
who require ECMO longer for lung recovery. In a 
study of prolonged ECMO published from the 
ELSO database in 2012, pediatric respiratory 
ECMO runs lasted ≥21  days in 12% of cases 
[116]. ECMO continues to be employed for 
increasingly sicker and more complex patients, 
which has likely led to more prolonged ECMO 
courses [24]. The current rate of prolonged 
ECMO may therefore be higher than 12%.
Children on ECMO for more than 21 days for 
acute respiratory failure have significantly worse 
survival, 38%, compared to 61% for less than 
14 days and 53% for 2–3 weeks [116] (Fig. 2.1). 
Survival in pediatric respiratory ECMO patients 
steadily decreases as length of ECMO increases 
from 5 days to 37 days, and there is a late steep 
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Fig. 2.1 Survival of 
patients to discharge as a 
function of days on 
ECMO (n = 3160). 
(Reproduced with 
permission from Brogan 
et al. [116])
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ECMO [116]. From 1993 to 2007, there were no 
survivors of the nine patients supported on 
ECMO for 52 days or more in the ELSO database 
[116]. More recently, there have been many cases 
reported of long-term respiratory ECMO in both 
children and adults with good outcomes, includ-
ing lung transplant or late lung recovery after up 
to 265 days of ECMO [116–121]. These reports 
are remarkable as, historically, it has been thought 
that if native lung function was not improving or 
restored at 2–4  weeks of ECMO support, the 
chance of recovery was remote [119]. As evi-
denced by these case reports of successful pro-
longed ECMO, there may be previously 
underappreciated regenerative capacity of the 
lungs. The paradigm for lung recovery may be 
more similar to recovery of kidney function after 
acute kidney injury, where the chances of recov-
ery of native function decrease over time, but 
there is still potential for return to normal func-
tion in some patients even weeks to months after 
injury.
The decision of when lung recovery becomes 
remote is difficult. There is a paucity of data to 
help physicians prognosticate which patients on 
prolonged ECMO may recover. Despite the lack 
of many survivors after 8  weeks on ECMO, 
reports of successful outcomes beyond this time 
frame suggest there should be no absolute cutoff 
for length of ECMO duration in pediatric respi-
ratory failure. It is therefore imperative to care-
fully assess patients on prolonged ECMO 
support in regard to proximate cause of respira-
tory failure, premorbid lung function, potential 
for lung recovery, presence of other organ dys-
functions, and the goals of the patient or 
decision-makers.
 ECMO as a Bridge to Lung Transplant
Patients who are on prolonged ECMO without 
recovery of native function may be candidates 
for lung transplant. The evaluation process for 
lung transplantation should be considered for 
patients on ECMO for greater than 3  weeks 
without a trajectory toward improvement or 
early in the ECMO course for patients with 
known progressive lung diseases such as 
CF. While consensus guidelines state that ECLS 
is a relative contraindication to lung transplanta-
tion, 1.5% of lung transplant recipients are 
bridged to transplant on ECMO [122, 123]. 
Patients bridged to lung transplant on ECMO 
may have worse short-term survival, but adult 
lung transplant recipients who are spontane-
ously breathing on ECMO have similar 3-year 
survival to patients on no support and better sur-
vival than patients on mechanical ventilation 
alone or on ECMO with mechanical ventilation 
[123, 124].
 Considerations on Prolonged ECMO
When a patient is supported on prolonged 
ECMO, other important considerations are reha-
bilitation and tracheostomy. Tracheostomy on 
ECMO is not common practice in pediatrics, 
with only 13% of pediatric centers reporting per-
forming tracheostomies in these patients [90]. 
The placement of tracheostomy while on ECMO 
is more frequently performed in adults [90]. To 
our knowledge, the largest report of tracheos-
tomy on ECMO at a pediatric institution con-
tains nine patients ages 7–25 years [125]. Two of 
nine survived without lung transplantation, and 
four survived with lung transplantation. All 
patients had decreased sedation needs within 
72 h. The biggest concern with performing tra-
cheostomy on ECMO is bleeding due to antico-
agulation. Practices for anticoagulation vary 
from holding of anticoagulation around the time 
of procedure to varying reductions in heparin 
dosing [90, 125]. In two adult case series of 168 
ECMO patients in total, minor bleeding after tra-
cheostomy was common (approximately 30%), 
while major bleeding occurred in only 2% and 
8% of cases. No deaths were attributed to com-
plications of tracheostomy [126, 127]. If trache-
ostomy is to be considered, the timing of 
tracheostomy remains a difficult decision. The 
average time on ECMO to tracheostomy in the 
pediatric study of nine patients was 10  days 
[125]. Older pediatric patients with longer than 
average expected ECMO durations or those on 
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ECMO as a bridge to lung transplant are most 
likely to benefit. These patients may be able to 
tolerate decreases in sedation and actively par-
ticipate in rehabilitation due to developmental 
stage. These patients are also the same subset of 
children that may benefit from extubation on 
ECMO. Tracheostomy is a higher risk than extu-
bation due to bleeding complications but would 
be preferred when the ECMO circuit cannot sup-
port oxygenation without positive-pressure 
ventilation.
The other major consideration for patients on 
prolonged ECMO is rehabilitation. Patients on 
ECMO often have multiple risk factors for ICU- 
related neuromuscular weakness including corti-
costeroids, neuromuscular blockade, systemic 
inflammation, immobility, hyperglycemia, and 
multiorgan failure [128]. Physical therapy with 
mobilization is common on ECMO, but ambula-
tion of patients on ECMO is rare [125, 129, 130]. 
Ambulation on ECMO is a difficult process but 
can be accomplished safely with a coordinated 
team approach and either extubation or tracheos-
tomy to eliminate the precarious endotracheal 
tube.
Children on ECMO as a bridge to lung trans-
plantation who participate in rehabilitation have 
shorter length of ventilation after transplant and 
shorter length of ICU stay compared to those 
who do not participate in rehabilitation [130]. 
Additionally, patients ambulated on ECMO 
have lower hospital costs than those who do not 
ambulate [131]. In a survey of 208 adult ECMO 
centers, major barriers to ambulation identified 
included concerns about hemodynamic instabil-
ity, hypoxemia, and femoral cannulation [132]. 
In pediatrics, these barriers are present, but 
there is additional concern for cannula move-
ment. Pediatric patients have a smaller margin 
for error in the location of cannula, especially 
when a bicaval cannula is being used for 
V-V-ECMO.
We suggest physical therapy in all patients on 
ECMO for acute respiratory failure if oxygen-
ation and hemodynamics tolerate it. Patients who 
are likely to be on prolonged ECMO, if able to be 
extubated or has a tracheostomy in place, may 
benefit from more aggressive rehabilitation such 
as ambulation.
 Termination of Extracorporeal 
Support
ECMO is a resource-intense, high-risk techno-
logical modality that can provide extended 
respiratory support for children with respira-
tory failure. Within this framework, ECMO 
serves as a bridge to a destination for each child 
it supports. Potential pathways include bridge 
to a diagnosis, bridge to recovery, and bridge to 
lung transplantation. Making diagnostic deter-
minations and outlining criteria for lung trans-
plantation are typically concrete decisions 
within the medical team’s grasp. Likewise, the 
development of a catastrophic complication 
(e.g., massive hemorrhagic stroke) on ECMO 
renders the decision to terminate ECMO sup-
port, in most instances, straightforward. But in 
the absence of such a complication, our ability 
to predict pulmonary recovery is fraught with 
difficulty and uncertainty. Much of this com-
plexity is related to the tremendous amount of 
heterogeneity within our patient population in 
the pediatric ICU, including diagnosis, age, 
comorbidities, and many of the other factors 
discussed in the preceding sections. Decision-
making around prolonged ECMO support is 
challenging due to these limitations, and the 
clinical team may find uncertainty as to whether 
pulmonary recovery is still possible or if con-
tinuing ECMO now reached the point of futil-
ity. A multidisciplinary discussion of prognosis 
and probability of lung recovery should be ini-
tiated by 3 weeks of support, when the chance 
of survival begins to decline [116]. Current rec-
ommendations in the ethics literature suggest a 
careful analysis for potentially inappropriate 
care ECMO when respiratory support reaches 
2–3 months [133].
Importantly, the potential for non-recovery 
and the possibility of termination of ECMO sup-
port should be introduced and communicated to 
the child’s family during the initial informed con-
sent process prior to commencement of 
ECMO.  However, several issues make true 
informed consent difficult, if not sometimes 
impossible, during these conversations such as 
complex and unfamiliar technology, uncertainty 
regarding diagnosis and prognosis, limited time 
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for discussion due to acuity of the clinical situa-
tion, and a sense of urgency conveyed by the 
medical team [134]. The specific necessity of 
withdrawal of ECMO support in cases of futility 
is recommended as a standard component of the 
consent form for ECMO [133]. Second, P-PREP 
[135] and Ped-RESCUER [136] are recently val-
idated prediction models that help pediatric 
intensivists estimate the mortality risk for chil-
dren with respiratory failure at the time of initia-
tion of ECMO (Table 2.2). Both models consider 
patient diagnosis, several pre-ECMO variables, 
and accompanying comorbidities. While not per-
fect tools, P-PREP and Ped-RESCUERS can pro-
vide the clinical team guidance when counseling 
families regarding their child’s risk of dying on 
ECMO.
 Conclusion
In summary, ECMO continues to be an available 
modality to support children with the most severe 
forms of hypoxemic and hypercarbic respiratory 
failure. Ideal candidates for ECMO are those 
patients with reversible lung injury or those 
whom could be considered for lung transplanta-
tion in the event of non-recovery. V-V ECMO is 
the ideal extracorporeal modality to support these 
patients if left ventricular function is not 
depressed. Single-site cannulation utilizing 
double- lumen ECMO catheters is becoming the 
standard technique by which to obtain vascular 
access for V-V ECMO.  Once on ECMO, ideal 
strategies for mechanical ventilation include a 
moderate-to-high degree of PEEP to maintain 
alveolar recruitment while minimizing plateau 
pressures to avoid further lung injury. As clinical 
experience with ECMO for pediatric respiratory 
failure continues to increase, we will have a bet-
ter understanding of the optimal means of using 
this technology as well as its limitations.
Table 2.2 Components mortality scores for children 
with respiratory failure on ECMO
PPREPa Ped-RESCUERSb
V-A ECMO ×
Time from admit to 
ECMO
×




Mode of ventilation ×
Mean airway pressure ×
Primary diagnosis:
  Asthma ×
  Aspiration ×
  Bronchiolitis ×
  Pertussis × ×
  RSV ×
  Sepsis-induced ARDS ×
Comorbid conditions:
  Pre-ECMO arrest ×
  Cancer × ×
  ARF ×
  Acute liver necrosis ×
Year of ECMO ×
Milrinone infusion ×
aPediatric pulmonary rescue with extracorporeal mem-
brane oxygenation prediction
bPediatric risk estimate score for children using extracor-
poreal respiratory support
h t t p s : / / w w w . e l s o . o r g / R e s o u r c e s / E C M O 
OutcomePredictionScores.aspx
Take-Home Points
• ECMO candidacy evaluation requires 
holistic approach to the patient, includ-
ing evaluation of the cause of respira-
tory failure, the trajectory of disease, 
and comorbidities.
• Venovenous ECMO support is the pre-
ferred configuration for pediatric respi-
ratory failure when feasible.
• The goal of mechanical ventilation on 
ECMO is to limit ventilator-induced 
injury; however, the best strategy is yet 
to be determined.
• Prolonged ECMO for respiratory failure 
in children has an increased risk of mor-
tality, with the risk consistently rising 
after the first few weeks on ECMO.
• Center ECMO volumes may play a role 
in patient outcomes, but these are likely 
age- and disease-specific. Centers with 
low ECMO volumes should use other 
methods to maintain competency, such 
as simulation.
2 Extracorporeal Membrane Oxygenation for Acute Pediatric Respiratory Failure
36
References
 1. ECMO. Registry of the Extracorporeal Life Support 
Organization (ELSO). Ann Arbor: Extracorporeal 
Life Support Organization; 2017.
 2. O’Rourke PP, Crone RK, Vacanti JP, Ware JH, 
Lillehei CW, Parad RB, et al. Extracorporeal mem-
brane oxygenation and conventional medical therapy 
in neonates with persistent pulmonary hypertension 
of the newborn: a prospective randomized study. 
Pediatrics. 1989;84(6):957–63.
 3. UK Collaborative ECMO Trail Group. UK col-
laborative randomised trial of neonatal extra-
corporeal membrane oxygenation. Lancet. 
1996;348(9020):75–82.
 4. Mugford M, Elbourne D, Field D.  Extracorporeal 
membrane oxygenation for severe respiratory failure 
in newborn infants. Cochrane Database Syst Rev. 
2008;3:CD001340.
 5. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, 
Allen E, Thalanany MM, et  al. Efficacy and eco-
nomic assessment of conventional ventilatory sup-
port versus extracorporeal membrane oxygenation 
for severe adult respiratory failure (CESAR): a 
multicentre randomised controlled trial. Lancet. 
2009;374(9698):1351–63.
 6. Curley MA, Wypij D, Watson RS, Grant MJ, Asaro 
LA, Cheifetz IM, et  al. Protocolized sedation vs 
usual care in pediatric patients mechanically ven-
tilated for acute respiratory failure: a randomized 
clinical trial. JAMA. 2015;313(4):379–89.
 7. Barbaro RP, Xu Y, Borasino S, Truemper EJ, 
Watson RS, Thiagarajan RR, et  al. Does extra-
corporeal membrane oxygenation improve sur-
vival in pediatric acute respiratory failure? Am J 
Respir Crit Care Med. 2018;197:1177.
 8. Beitler JR, Malhotra A, Thompson BT.  Ventilator- 
induced lung injury. Clin Chest Med. 
2016;37(4):633–46.
 9. Rimensberger PC, Cheifetz IM, Pediatric Acute 
Lung Injury Consensus Conference Group. 
Ventilatory support in children with pediatric acute 
respiratory distress syndrome: proceedings from the 
Pediatric Acute Lung Injury Consensus Conference. 
Pediatr Crit Care Med. 2015;16(5 Suppl 1):S51–60.
 10. Flori HR, Glidden DV, Rutherford GW, Matthay 
MA. Pediatric acute lung injury: prospective evalu-
ation of risk factors associated with mortality. Am J 
Respir Crit Care Med. 2005;171(9):995–1001.
 11. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld 
GD. Incidence and outcomes of pediatric acute lung 
injury. Pediatrics. 2009;124(1):87–95.
 12. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, 
Pittet JF, Eisner MD, et  al. Pulmonary dead-space 
fraction as a risk factor for death in the acute 
respiratory distress syndrome. N Engl J Med. 
2002;346(17):1281–6.
 13. Bhalla AK, Belani S, Leung D, Newth CJ, Khemani 
RG. Higher dead space is associated with increased 
mortality in critically ill children. Crit Care Med. 
2015;43(11):2439–45.
 14. Yehya N, Bhalla AK, Thomas NJ, Khemani 
RG.  Alveolar dead space fraction discriminates 
mortality in pediatric acute respiratory distress syn-
drome. Pediatr Crit Care Med. 2016;17(2):101–9.
 15. Khemani RG, Smith LS, Zimmerman JJ, Erickson S, 
Pediatric Acute Lung Injury Consensus Conference 
Group. Pediatric acute respiratory distress syn-
drome: definition, incidence, and epidemiology: 
proceedings from the Pediatric Acute Lung Injury 
Consensus Conference. Pediatr Crit Care Med. 
2015;16(5 Suppl 1):S23–40.
 16. Trachsel D, McCrindle BW, Nakagawa S, Bohn 
D. Oxygenation index predicts outcome in children 
with acute hypoxemic respiratory failure. Am J 
Respir Crit Care Med. 2005;172(2):206–11.
 17. Erickson S, Schibler A, Numa A, Nuthall G, Yung 
M, Pascoe E, et  al. Acute lung injury in pediatric 
intensive care in Australia and New Zealand: a pro-
spective, multicenter, observational study. Pediatr 
Crit Care Med. 2007;8(4):317–23.
 18. Khemani RG, Conti D, Alonzo TA, Bart RD 3rd, 
Newth CJ.  Effect of tidal volume in children with 
acute hypoxemic respiratory failure. Intensive Care 
Med. 2009;35(8):1428–37.
 19. Raj SSJ, Rigby M.  Factors associated with sur-
vival during high-frequency oscillatory ven-
tilation in children. J Pediatr Intensive Care. 
2015;4(3):146–55.
 20. Curley MA, Hibberd PL, Fineman LD, Wypij D, 
Shih MC, Thompson JE, et al. Effect of prone posi-
tioning on clinical outcomes in children with acute 
lung injury: a randomized controlled trial. JAMA. 
2005;294(2):229–37.
 21. Willson DF, Thomas NJ, Markovitz BP, Bauman 
LA, DiCarlo JV, Pon S, et  al. Effect of exog-
enous surfactant (calfactant) in pediatric acute 
lung injury: a randomized controlled trial. JAMA. 
2005;293(4):470–6.
 22. Zinter MS, Orwoll BE, Spicer AC, Alkhouli MF, 
Calfee CS, Matthay MA, et  al. Incorporating 
inflammation into mortality risk in pediatric acute 
respiratory distress syndrome. Crit Care Med. 
2017;45(5):858–66.
 23. Domico MB, Ridout DA, Bronicki R, Anas 
NG, Cleary JP, Cappon J, et  al. The impact 
of mechanical ventilation time before initia-
tion of extracorporeal life support on survival 
in pediatric respiratory failure: a review of the 
Extracorporeal Life Support Registry. Pediatr 
Crit Care Med. 2012;13(1):16–21.
 24. Zabrocki LA, Brogan TV, Statler KD, Poss WB, 
Rollins MD, Bratton SL.  Extracorporeal mem-
brane oxygenation for pediatric respiratory fail-
ure: survival and predictors of mortality. Crit 
Care Med. 2011;39(2):364–70.
 25. General Guidelines for all ECLS Cases. 
Extracorporeal Life Support Organization. 
2013;1.3:24.
M. Friedman and M. Hobson
37
 26. Dalton HJ, Macrae DJ, Pediatric Acute 
Lung Injury Consensus Conference Group. 
Extracorporeal support in children with pedi-
atric acute respiratory distress syndrome: pro-
ceedings from the Pediatric Acute Lung Injury 
Consensus Conference. Pediatr Crit Care Med. 
2015;16(5 Suppl 1):S111–7.
 27. Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney 
cross-talk in the critically ill patient. Am J Respir 
Crit Care Med. 2016;194(4):402–14.
 28. Santschi M, Randolph AG, Rimensberger PC, 
Jouvet P, Pediatric Acute Lung Injury Mechanical 
Ventilation I, Pediatric Acute Lung I, et  al. 
Mechanical ventilation strategies in children with 
acute lung injury: a survey on stated practice pattern. 
Pediatr Crit Care Med. 2013;14(7):e332–7.
 29. Acute Respiratory Distress Syndrome Network, 
Brower RG, Matthay MA, Morris A, Schoenfeld D, 
Thompson BT, et al. Ventilation with lower tidal vol-
umes as compared with traditional tidal volumes for 
acute lung injury and the acute respiratory distress 
syndrome. N Engl J Med. 2000;342(18):1301–8.
 30. Barnes T, Zochios V, Parhar K. Re-examining per-
missive hypercapnia in ARDS: a narrative review. 
Chest. 2017;154(1):185–95.
 31. Barbaro RP, Paden ML, Guner YS, Raman L, Ryerson 
LM, Alexander P, et al. Pediatric Extracorporeal Life 
Support Organization Registry International Report 
2016. ASAIO J. 2017;63(4):456–63.
 32. Hebbar KB, Petrillo-Albarano T, Coto-Puckett W, 
Heard M, Rycus PT, Fortenberry JD.  Experience 
with use of extracorporeal life support for severe 
refractory status asthmaticus in children. Crit Care. 
2009;13(2):R29.
 33. Hayes D Jr, Kopp BT, Preston TJ, Kirkby S, Tobias 
JD, Papadimos TJ, et al. Survival of patients with cys-
tic fibrosis on ECMO: analysis of the Extracorporeal 
Life Support Organization Registry. Int J Clin Exp 
Med. 2014;7(5):1370–2.
 34. Daoud O, Augustin P, Mordant P, Lasocki S, 
Al-Attar N, Maury JM, et al. Extracorporeal mem-
brane oxygenation in 5 patients with bronchial 
 fistula with severe acute lung injury. Ann Thorac 
Surg. 2011;92(1):327–30.
 35. Dolgner A, Bain J, Peterson-Carmichael SL, 
Turner DA, Rehder KJ.  Extracorporeal mem-
brane oxygenation for refractory air leak in a child 
presenting with bacterial tracheitis. Respir Care. 
2014;59(10):e163–5.
 36. Raake J, Johnson B, Seger B, Manning PB, 
Eghtesady P, Boesch P, et al. Extracorporeal mem-
brane oxygenation, extubation, and lung-recruitment 
maneuvers as rescue therapy in a patient with tra-
cheal dehiscence following slide tracheoplasty. 
Respir Care. 2011;56(8):1198–202.
 37. Hoetzenecker K, Klepetko W, Keshavjee S, Cypel 
M.  Extracorporeal support in airway surgery. J 
Thorac Dis. 2017;9(7):2108–17.
 38. Sapru A, Flori H, Quasney MW, Dahmer MK, 
Pediatric Acute Lung Injury Consensus Conference 
Group. Pathobiology of acute respiratory distress 
syndrome. Pediatr Crit Care Med. 2015;16(5 Suppl 
1):S6–22.
 39. Askegard-Giesmann JR, Besner GE, Fabia R, 
Caniano DA, Preston T, Kenney BD. Extracorporeal 
membrane oxygenation as a lifesaving modality in the 
treatment of pediatric patients with burns and respi-
ratory failure. J Pediatr Surg. 2010;45(6):1330–5.
 40. Skarda D, Henricksen JW, Rollins M. Extracorporeal 
membrane oxygenation promotes survival in chil-
dren with trauma related respiratory failure. Pediatr 
Surg Int. 2012;28(7):711–4.
 41. Fortenberry JD, Meier AH, Pettignano R, Heard M, 
Chambliss CR, Wulkan M. Extracorporeal life sup-
port for posttraumatic acute respiratory distress syn-
drome at a children’s medical center. J Pediatr Surg. 
2003;38(8):1221–6.
 42. Scalzo AJ, Weber TR, Jaeger RW, Connors RH, 
Thompson MW. Extracorporeal membrane oxygen-
ation for hydrocarbon aspiration. Am J Dis Child. 
1990;144(8):867–71.
 43. Kimura D, Shah S, Briceno-Medina M, Sathanandam 
S, Haberman B, Zhang J, et al. Management of mas-
sive diffuse alveolar hemorrhage in a child with 
systemic lupus erythematosus. J Intensive Care. 
2015;3:10.
 44. Zulian F, Martinez Toledo MM, Amigoni A, Martini 
G, Agosto C, Pettenazzo A. Successful use of extra-
corporeal membrane oxygenation for severe inter-
stitial lung disease in a child with dermatomyositis. 
Intensive Care Med. 2007;33(9):1663–6.
 45. Lopez-Fernandez Y, Azagra AM, de la Oliva P, 
Modesto V, Sanchez JI, Parrilla J, et  al. Pediatric 
acute lung injury epidemiology and natural history 
study: incidence and outcome of the acute respira-
tory distress syndrome in children. Crit Care Med. 
2012;40(12):3238–45.
 46. Halasa NB, Barr FE, Johnson JE, Edwards KM. Fatal 
pulmonary hypertension associated with pertussis in 
infants: does extracorporeal membrane oxygenation 
have a role? Pediatrics. 2003;112(6 Pt 1):1274–8.
 47. Sawal M, Cohen M, Irazuzta JE, Kumar R, Kirton 
C, Brundler MA, et al. Fulminant pertussis: a multi-
center study with new insights into the clinico- 
pathological mechanisms. Pediatr Pulmonol. 
2009;44(10):970–80.
 48. Surridge J, Segedin ER, Grant CC. Pertussis requiring 
intensive care. Arch Dis Child. 2007;92(11):970–5.
 49. Rowlands HE, Goldman AP, Harrington K, Karimova 
A, Brierley J, Cross N, et al. Impact of rapid leukode-
pletion on the outcome of severe clinical pertussis in 
young infants. Pediatrics. 2010;126(4):e816–27.
 50. Stewart DL, Cook LN, Rabalais GP. Successful use 
of extracorporeal membrane oxygenation in a new-
born with herpes simplex virus pneumonia. Pediatr 
Infect Dis J. 1993;12(2):161–2.
 51. Bonacchi M, Di Lascio G, Harmelin G, Pasquini 
A, Peris A, Sani G. Extracorporeal membrane oxy-
genation for refractory, life-threatening, and herpes 
simplex virus 1-induced acute respiratory distress 
2 Extracorporeal Membrane Oxygenation for Acute Pediatric Respiratory Failure
38
syndrome. Our experience and literature review. Am 
J Emerg Med. 2012;30(6):1014.e3–e10.
 52. Prodhan P, Wilkes R, Ross A, Garcia X, Bhutta AT, 
Rycus P, et al. Neonatal herpes virus infection and 
extracorporeal life support. Pediatr Crit Care Med. 
2010;11(5):599–602.
 53. Pluim T, Halasa N, Phillips SE, Fleming G.  The 
morbidity and mortality of patients with fungal 
infections before and during extracorporeal mem-
brane oxygenation support. Pediatr Crit Care Med. 
2012;13(5):e288–93.
 54. Creech CB, Johnson BG, Bartilson RE, Yang E, Barr 
FE. Increasing use of extracorporeal life support in 
methicillin-resistant Staphylococcus aureus sepsis in 
children. Pediatr Crit Care Med. 2007;8(3):231–5; 
quiz 47.
 55. Bridges BC, Hardison D, Pietsch J.  A case series 
of the successful use of ECMO, continuous renal 
replacement therapy, and plasma exchange for 
thrombocytopenia-associated multiple organ failure. 
J Pediatr Surg. 2013;48(5):1114–7.
 56. Kawai Y, Cornell TT, Cooley EG, Beckman CN, 
Baldridge PK, Mottes TA, et al. Therapeutic plasma 
exchange may improve hemodynamics and organ 
failure among children with sepsis-induced mul-
tiple organ dysfunction syndrome receiving extra-
corporeal life support. Pediatr Crit Care Med. 
2015;16(4):366–74.
 57. Moler FW, Palmisano J, Custer JR. Extracorporeal 
life support for pediatric respiratory failure: predic-
tors of survival from 220 patients. Crit Care Med. 
1993;21(10):1604–11.
 58. Pranikoff T, Hirschl RB, Steimle CN, Anderson HL 
3rd, Bartlett RH. Mortality is directly related to the 
duration of mechanical ventilation before the initia-
tion of extracorporeal life support for severe respira-
tory failure. Crit Care Med. 1997;25(1):28–32.
 59. Australia, New Zealand Extracorporeal Membrane 
Oxygenation Influenza Influenza Investigators, 
Davies A, Jones D, Bailey M, Beca J, et  al. 
Extracorporeal membrane oxygenation for 2009 
influenza A(H1N1) acute respiratory distress syn-
drome. JAMA. 2009;302(17):1888–95.
 60. Nance ML, Nadkarni VM, Hedrick HL, Cullen 
JA, Wiebe DJ. Effect of preextracorporeal mem-
brane oxygenation ventilation days and age 
on extracorporeal membrane oxygenation sur-
vival in critically ill children. J Pediatr Surg. 
2009;44(8):1606–10.
 61. Noah MA, Peek GJ, Finney SJ, Griffiths MJ, 
Harrison DA, Grieve R, et al. Referral to an extra-
corporeal membrane oxygenation center and mor-
tality among patients with severe 2009 influenza 
A(H1N1). JAMA. 2011;306(15):1659–68.
 62. Fleming GM, Sahay R, Zappitelli M, King E, 
Askenazi DJ, Bridges BC, et  al. The incidence 
of acute kidney injury and its effect on neonatal 
and pediatric extracorporeal membrane oxygen-
ation outcomes: a multicenter report from the kid-
ney intervention during extracorporeal membrane 
oxygenation study group. Pediatr Crit Care Med. 
2016;17(12):1157–69.
 63. Selewski DT, Askenazi DJ, Bridges BC, Cooper DS, 
Fleming GM, Paden ML, et al. The impact of fluid 
overload on outcomes in children treated with extra-
corporeal membrane oxygenation: a multicenter 
retrospective cohort study. Pediatr Crit Care Med. 
2017;18(12):1126–35.
 64. Gow KW, Heiss KF, Wulkan ML, Katzenstein HM, 
Rosenberg ES, Heard ML, et  al. Extracorporeal 
life support for support of children with malig-
nancy and respiratory or cardiac failure: the extra-
corporeal life support experience. Crit Care Med. 
2009;37(4):1308–16.
 65. Jacobe SJ, Hassan A, Veys P, Mok Q. Outcome of 
children requiring admission to an intensive care 
unit after bone marrow transplantation. Crit Care 
Med. 2003;31(5):1299–305.
 66. Lamas A, Otheo E, Ros P, Vazquez JL, Maldonado 
MS, Munoz A, et  al. Prognosis of child recipi-
ents of hematopoietic stem cell transplantation 
requiring intensive care. Intensive Care Med. 
2003;29(1):91–6.
 67. Keenan HT, Bratton SL, Martin LD, Crawford 
SW, Weiss NS.  Outcome of children who require 
mechanical ventilatory support after bone marrow 
transplantation. Crit Care Med. 2000;28(3):830–5.
 68. Rowan CM, Loomis A, McArthur J, Smith LS, Gertz 
SJ, Fitzgerald JC, et al. High-frequency oscillatory 
ventilation use and severe pediatric ARDS in the 
pediatric hematopoietic cell transplant recipient. 
Respir Care. 2017;63:404.
 69. Morris SH, Haight AE, Kamat P, Fortenberry 
JD.  Successful use of extracorporeal life support 
in a hematopoietic stem cell transplant patient with 
diffuse alveolar hemorrhage. Pediatr Crit Care Med. 
2010;11(1):e4–7.
 70. Liao WI, Tsai SH, Chiu SK. Successful use of extra-
corporeal membrane oxygenation in a hematopoietic 
stem cell transplant patient with idiopathic pneumo-
nia syndrome. Respir Care. 2013;58(2):e6–10.
 71. Wolfson RK, Kahana MD, Nachman JB, Lantos 
J.  Extracorporeal membrane oxygenation after 
stem cell transplant: clinical decision-making in 
the absence of evidence. Pediatr Crit Care Med. 
2005;6(2):200–3.
 72. Gow KW, Wulkan ML, Heiss KF, Haight AE, Heard 
ML, Rycus P, et al. Extracorporeal membrane oxy-
genation for support of children after hematopoietic 
stem cell transplantation: the Extracorporeal Life 
Support Organization experience. J Pediatr Surg. 
2006;41(4):662–7.
 73. Di Nardo M, Locatelli F, Palmer K, Amodeo A, 
Lorusso R, Belliato M, et al. Extracorporeal mem-
brane oxygenation in pediatric recipients of hemato-
poietic stem cell transplantation: an updated analysis 
of the Extracorporeal Life Support Organization 
experience. Intensive Care Med. 2014;40(5):754–6.
 74. Brogan TVL, Lequier L, Lorusso R, MacLaren 
G, Peek G.  Extracorporeal life support: the ELSO 
M. Friedman and M. Hobson
39
red book. 5th ed. Ann Arbor: Extracorporeal Life 
Support Organization; 2017.
 75. Teele SA, Salvin JW, Barrett CS, Rycus PT, Fynn- 
Thompson F, Laussen PC, et al. The association of 
carotid artery cannulation and neurologic injury in 
pediatric patients supported with venoarterial extra-
corporeal membrane oxygenation. Pediatr Crit Care 
Med. 2014;15(4):355–61.
 76. Rollins MD, Hubbard A, Zabrocki L, Barnhart DC, 
Bratton SL. Extracorporeal membrane oxygenation 
cannulation trends for pediatric respiratory failure 
and central nervous system injury. J Pediatr Surg. 
2012;47(1):68–75.
 77. Pettignano R, Fortenberry JD, Heard ML, Labuz 
MD, Kesser KC, Tanner AJ, et al. Primary use of the 
venovenous approach for extracorporeal membrane 
oxygenation in pediatric acute respiratory failure. 
Pediatr Crit Care Med. 2003;4(3):291–8.
 78. Skinner SC, Iocono JA, Ballard HO, Turner MD, 
Ward AN, Davenport DL, et  al. Improved sur-
vival in venovenous vs venoarterial extracorporeal 
membrane oxygenation for pediatric noncardiac 
sepsis patients: a study of the Extracorporeal Life 
Support Organization registry. J Pediatr Surg. 
2012;47(1):63–7.
 79. Rehder KJ, Turner DA, Cheifetz IM. Extracorporeal 
membrane oxygenation for neonatal and pediatric 
respiratory failure: an evidence-based review of the 
past decade (2002–2012). Pediatr Crit Care Med. 
2013;14(9):851–61.
 80. Zamora IJ, Shekerdemian L, Fallon SC, Olutoye 
OO, Cass DL, Rycus PL, et al. Outcomes compar-
ing dual-lumen to multisite venovenous ECMO 
in the pediatric population: the Extracorporeal 
Life Support Registry experience. J Pediatr Surg. 
2014;49(10):1452–7.
 81. Subramanian S, Vafaeezadeh M, Parrish AR, 
McMullan DM. Comparison of wire-reinforced and 
non-wire-reinforced dual-lumen catheters for veno-
venous ECMO in neonates and infants. ASAIO J. 
2013;59(1):81–5.
 82. Javidfar J, Brodie D, Wang D, Ibrahimiye AN, 
Yang J, Zwischenberger JB, et  al. Use of bicaval 
dual-lumen catheter for adult venovenous extracor-
poreal membrane oxygenation. Ann Thorac Surg. 
2011;91(6):1763–8; discussion 9.
 83. Teman NR, Haft JW, Napolitano LM.  Optimal 
endovascular methods for placement of bica-
val dual-lumen cannulae for venovenous extra-
corporeal membrane oxygenation. ASAIO J. 
2013;59(4):442–7.
 84. Fallon SC, Shekerdemian LS, Olutoye OO, Cass 
DL, Zamora IJ, Nguyen T, et  al. Initial experience 
with single-vessel cannulation for venovenous 
extracorporeal membrane oxygenation in pedi-
atric respiratory failure. Pediatr Crit Care Med. 
2013;14(4):366–73.
 85. Lazar DA, Cass DL, Olutoye OO, Kim ES, Welty 
SE, Fernandes CJ, et  al. Venovenous cannulation 
for extracorporeal membrane oxygenation using a 
 bicaval dual-lumen catheter in neonates. J Pediatr 
Surg. 2012;47(2):430–4.
 86. Jarboe MD, Gadepalli SK, Church JT, Arnold MA, 
Hirschl RB, Mychaliska GB. Avalon catheters in pedi-
atric patients requiring ECMO: placement and migra-
tion problems. J Pediatr Surg. 2018;53(1):159–62.
 87. Conrad SA, Grier LR, Scott LK, Green R, Jordan 
M.  Percutaneous cannulation for extracorporeal 
membrane oxygenation by intensivists: a retrospec-
tive single-institution case series. Crit Care Med. 
2015;43(5):1010–5.
 88. Marhong JD, Telesnicki T, Munshi L, Del Sorbo 
L, Detsky M, Fan E.  Mechanical ventilation dur-
ing extracorporeal membrane oxygenation. 
An international survey. Ann Am Thorac Soc. 
2014;11(6):956–61.
 89. Marhong JD, Munshi L, Detsky M, Telesnicki T, Fan 
E. Mechanical ventilation during extracorporeal life 
support (ECLS): a systematic review. Intensive Care 
Med. 2015;41(6):994–1003.
 90. Jenks CL, Tweed J, Gigli KH, Venkataraman R, 
Raman L. An international survey on ventilator prac-
tices among extracorporeal membrane oxygenation 
centers. ASAIO J. 2017;63(6):787–92.
 91. Camporota L, Nicoletti E, Malafronte M, De Neef 
M, Mongelli V, Calderazzo MA, et al. International 
survey on the management of mechanical ventilation 
during ECMO in adults with severe respiratory fail-
ure. Minerva Anestesiol. 2015;81(11):1170–83, 77 p 
following 83.
 92. Roy S, Habashi N, Sadowitz B, Andrews P, Ge L, 
Wang G, et al. Early airway pressure release ventila-
tion prevents ARDS-a novel preventive approach to 
lung injury. Shock. 2013;39(1):28–38.
 93. Keszler M, Ryckman FC, McDonald JV Jr, Sweet 
LD, Moront MG, Boegli MJ, et  al. A prospec-
tive, multicenter, randomized study of high ver-
sus low positive end-expiratory pressure during 
extracorporeal membrane oxygenation. J Pediatr. 
1992;120(1):107–13.
 94. Keszler M, Subramanian KN, Smith YA, Dhanireddy 
R, Mehta N, Molina B, et  al. Pulmonary manage-
ment during extracorporeal membrane oxygenation. 
Crit Care Med. 1989;17(6):495–500.
 95. Schmidt M, Stewart C, Bailey M, Nieszkowska A, 
Kelly J, Murphy L, et  al. Mechanical ventilation 
management during extracorporeal membrane oxy-
genation for acute respiratory distress syndrome: a 
retrospective international multicenter study. Crit 
Care Med. 2015;43(3):654–64.
 96. Modrykamien AM, Hernandez OO, Im Y, Walters 
RW, Schrader CL, Smith LE, et  al. Mechanical 
ventilation in patients with the acute respira-
tory distress syndrome and treated with extra-
corporeal membrane oxygenation: impact on 
hospital and 30 day postdischarge survival. ASAIO 
J. 2016;62(5):607–12.
 97. Protti A, Andreis DT, Monti M, Santini A, 
Sparacino CC, Langer T, et  al. Lung stress and 
strain during mechanical ventilation: any  difference 
2 Extracorporeal Membrane Oxygenation for Acute Pediatric Respiratory Failure
40
between statics and dynamics? Crit Care Med. 
2013;41(4):1046–55.
 98. Chu EK, Whitehead T, Slutsky AS. Effects of cyclic 
opening and closing at low- and high-volume ven-
tilation on bronchoalveolar lavage cytokines. Crit 
Care Med. 2004;32(1):168–74.
 99. Tsuchida S, Engelberts D, Peltekova V, Hopkins N, 
Frndova H, Babyn P, et al. Atelectasis causes alveo-
lar injury in nonatelectatic lung regions. Am J Respir 
Crit Care Med. 2006;174(3):279–89.
 100. Franchineau G, Brechot N, Lebreton G, Hekimian 
G, Nieszkowska A, Trouillet JL, et al. Bedside con-
tribution of electrical impedance tomography to 
setting positive end-expiratory pressure for extracor-
poreal membrane oxygenation-treated patients with 
severe acute respiratory distress syndrome. Am J 
Respir Crit Care Med. 2017;196(4):447–57.
 101. Chiu LC, Hu HC, Hung CY, Chang CH, Tsai FC, 
Yang CT, et  al. Dynamic driving pressure associ-
ated mortality in acute respiratory distress syndrome 
with extracorporeal membrane oxygenation. Ann 
Intensive Care. 2017;7(1):12.
 102. Serpa Neto A, Schmidt M, Azevedo LC, Bein T, 
Brochard L, Beutel G, et  al. Associations between 
ventilator settings during extracorporeal membrane 
oxygenation for refractory hypoxemia and outcome 
in patients with acute respiratory distress syndrome: 
a pooled individual patient data analysis : mechani-
cal ventilation during ECMO. Intensive Care Med. 
2016;42(11):1672–84.
 103. de Jager P, Burgerhof JG, van Heerde M, Albers 
MJ, Markhorst DG, Kneyber MC.  Tidal vol-
ume and mortality in mechanically ventilated 
children: a systematic review and meta-anal-
ysis of observational studies. Crit Care Med. 
2014;42(12):2461–72.
 104. Kamat PP, Popler J, Davis J, Leong T, Piland SC, 
Simon D, et al. Use of flexible bronchoscopy in pedi-
atric patients receiving extracorporeal membrane 
oxygenation (ECMO) support. Pediatr Pulmonol. 
2011;46(11):1108–13.
 105. Prentice E, Mastropietro CW.  Flexible bronchos-
copy for children on extracorporeal membrane 
 oxygenation for cardiac failure. Pediatr Crit Care 
Med. 2011;12(4):422–5.
 106. Yehya N, Dominick CL, Connelly JT, Davis DH, 
Minneci PC, Deans KJ, et  al. High-frequency 
percussive ventilation and bronchoscopy during 
extracorporeal life support in children. ASAIO J. 
2014;60(4):424–8.
 107. Karlson KH Jr, Pickert CB, Schexnayder SM, 
Heulitt MJ.  Flexible fiberoptic bronchoscopy in 
children on extracorporeal membrane oxygenation. 
Pediatr Pulmonol. 1993;16(4):215–8.
 108. Lucangelo U, Fontanesi L, Antonaglia V, Pellis T, 
Berlot G, Liguori G, et al. High frequency percus-
sive ventilation (HFPV). Principles and technique. 
Minerva Anestesiol. 2003;69(11):841–8, 8–51.
 109. Bataillard A, Hebrard A, Gaide-Chevronnay L, 
Martin C, Durand M, Albaladejo P, et al. Extubation 
in patients undergoing extracorporeal life support. 
Int J Artif Organs. 2017;40(12):696–700.
 110. Freeman CL, Bennett TD, Casper TC, Larsen GY, 
Hubbard A, Wilkes J, et  al. Pediatric and neona-
tal extracorporeal membrane oxygenation: does 
center volume impact mortality? Crit Care Med. 
2014;42(3):512–9.
 111. Karamlou T, Vafaeezadeh M, Parrish AM, Cohen 
GA, Welke KF, Permut L, et al. Increased extracor-
poreal membrane oxygenation center case volume is 
associated with improved extracorporeal membrane 
oxygenation survival among pediatric patients. J 
Thorac Cardiovasc Surg. 2013;145(2):470–5.
 112. Barbaro RP, Odetola FO, Kidwell KM, Paden 
ML, Bartlett RH, Davis MM, et  al. Association 
of hospital-level volume of extracorporeal 
membrane oxygenation cases and mortality. 
Analysis of the extracorporeal life support orga-
nization registry. Am J Respir Crit Care Med. 
2015;191(8):894–901.
 113. Combes A, Brodie D, Bartlett R, Brochard L, Brower 
R, Conrad S, et al. Position paper for the organiza-
tion of extracorporeal membrane oxygenation pro-
grams for acute respiratory failure in adult patients. 
Am J Respir Crit Care Med. 2014;190(5):488–96.
 114. Chan SY, Figueroa M, Spentzas T, Powell A, 
Holloway R, Shah S.  Prospective assessment of 
novice learners in a simulation-based extracorporeal 
membrane oxygenation (ECMO) education pro-
gram. Pediatr Cardiol. 2013;34(3):543–52.
 115. Zakhary BM, Kam LM, Kaufman BS, Felner 
KJ. The utility of high-fidelity simulation for train-
ing critical care fellows in the management of 
extracorporeal membrane oxygenation emergen-
cies: a randomized controlled trial. Crit Care Med. 
2017;45(8):1367–73.
 116. Brogan TV, Zabrocki L, Thiagarajan RR, 
Rycus PT, Bratton SL.  Prolonged extracorpo-
real membrane oxygenation for children with 
respiratory failure. Pediatr Crit Care Med. 
2012;13(4):e249–54.
 117. Wiktor AJ, Haft JW, Bartlett RH, Park PK, 
Raghavendran K, Napolitano LM.  Prolonged VV 
ECMO (265 days) for ARDS without technical com-
plications. ASAIO J. 2015;61(2):205–6.
 118. Moon SM, Lee H, Moon JH, Kim HK, Park JE, 
Byeon S, et al. Prolonged maintenance of VV ECMO 
for 104 days with native lung recovery in acute respi-
ratory failure. ASAIO J. 2016;62(2):e15–7.
 119. Rosenberg AA, Haft JW, Bartlett R, Iwashyna TJ, 
Huang SK, Lynch WR, et  al. Prolonged duration 
ECMO for ARDS: futility, native lung recovery, or 
transplantation? ASAIO J. 2013;59(6):642–50.
 120. Iacono A, Groves S, Garcia J, Griffith B. Lung trans-
plantation following 107 days of extracorporeal 
membrane oxygenation. Eur J Cardiothorac Surg. 
2010;37(4):969–71.
 121. Gupta P, McDonald R, Chipman CW, Stroud M, 
Gossett JM, Imamura M, et  al. 20-year experience 
of prolonged extracorporeal membrane oxygenation 
M. Friedman and M. Hobson
41
in critically ill children with cardiac or pulmonary 
failure. Ann Thorac Surg. 2012;93(5):1584–90.
 122. Weill D, Benden C, Corris PA, Dark JH, Davis 
RD, Keshavjee S, et al. A consensus document for 
the selection of lung transplant candidates: 2014 – 
an update from the Pulmonary Transplantation 
Council of the International Society for Heart and 
Lung Transplantation. J Heart Lung Transplant. 
2015;34(1):1–15.
 123. Schechter MA, Ganapathi AM, Englum BR, 
Speicher PJ, Daneshmand MA, Davis RD, et  al. 
Spontaneously breathing extracorporeal mem-
brane oxygenation support provides the optimal 
bridge to lung transplantation. Transplantation. 
2016;100(12):2699–704.
 124. Toyoda Y, Bhama JK, Shigemura N, Zaldonis 
D, Pilewski J, Crespo M, et  al. Efficacy of extra-
corporeal membrane oxygenation as a bridge to 
lung transplantation. J Thorac Cardiovasc Surg. 
2013;145(4):1065–70; discussion 70–1.
 125. Schwartz SP, Bonadonna D, Hartwig MG, Cheifetz 
IM. Bedside tracheostomy on pediatric ICU subjects 
supported by extracorporeal membrane oxygen-
ation. Respir Care. 2017;62:1447.
 126. Kruit N, Valchanov K, Blaudszun G, Fowles JA, 
Vuylsteke A.  Bleeding complications associ-
ated with percutaneous tracheostomy insertion in 
patients supported with venovenous extracorpo-
real membrane oxygen support: a 10-year insti-
tutional experience. J Cardiothorac Vasc Anesth. 
2017;32:1162.
 127. Braune S, Kienast S, Hadem J, Wiesner O, 
Wichmann D, Nierhaus A, et  al. Safety of percu-
taneous dilatational tracheostomy in patients on 
extracorporeal lung support. Intensive Care Med. 
2013;39(10):1792–9.
 128. Zorowitz RD. ICU-acquired weakness: a rehabilita-
tion perspective of diagnosis, treatment, and func-
tional management. Chest. 2016;150(4):966–71.
 129. Abrams D, Javidfar J, Farrand E, Mongero LB, 
Agerstrand CL, Ryan P, et al. Early mobilization of 
patients receiving extracorporeal membrane oxy-
genation: a retrospective cohort study. Crit Care. 
2014;18(1):R38.
 130. Turner DA, Rehder KJ, Bonadonna D, Gray A, Lin 
S, Zaas D, et al. Ambulatory ECMO as a bridge to 
lung transplant in a previously well pediatric patient 
with ARDS. Pediatrics. 2014;134(2):e583–5.
 131. Bain JC, Turner DA, Rehder KJ, Eisenstein EL, 
Davis RD, Cheifetz IM, et al. Economic outcomes 
of extracorporeal membrane oxygenation with and 
without ambulation as a bridge to lung transplanta-
tion. Respir Care. 2016;61(1):1–7.
 132. Marhong JD, DeBacker J, Viau-Lapointe J, Munshi 
L, Del Sorbo L, Burry L, et al. Sedation and mobili-
zation during venovenous extracorporeal membrane 
oxygenation for acute respiratory failure: an interna-
tional survey. Crit Care Med. 2017;45(11):1893–9.
 133. Ramanathan K, Cove ME, Caleb MG, Teoh KL, 
Maclaren G.  Ethical dilemmas of adult ECMO: 
emerging conceptual challenges. J Cardiothorac 
Vasc Anesth. 2015;29(1):229–33.
 134. Peetz AB, Sadovnikoff N, O’Connor MF.  Is 
informed consent for extracorporeal life support 
even possible? AMA J Ethics. 2015;17(3):236–42.
 135. Bailly DK, Reeder RW, Zabrocki LA, Hubbard 
AM, Wilkes J, Bratton SL, et al. Development and 
validation of a score to predict mortality in children 
undergoing extracorporeal membrane oxygenation 
for respiratory failure: pediatric pulmonary rescue 
with extracorporeal membrane oxygenation predic-
tion score. Crit Care Med. 2017;45(1):e58–66.
 136. Barbaro RP, Boonstra PS, Paden ML, Roberts 
LA, Annich GM, Bartlett RH, et  al. Development 
and validation of the pediatric risk estimate score 
for children using extracorporeal respiratory sup-
port (Ped-RESCUERS). Intensive Care Med. 
2016;42(5):879–88.
2 Extracorporeal Membrane Oxygenation for Acute Pediatric Respiratory Failure
